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GENERAL	CONTENT	
	DIABETE	MELLITUS	
	
1.	DEFINITION	AND	DESCRIPTION	OF	DIABETES	MELLITUS	
Diabetes	mellitus	is	a	group	of	metabolic	diseases	characterized	by	hyperglycemia	resulting	from	
defects	 in	 insulin	 secretion,	 insulin	 action,	 or	 both.	 The	 chronic	 hyperglycemia	 of	 diabetes	 is	
associated	with	long-term	damage,	dysfunction,	and	failure	of	various	organs,	especially	the	eyes,	
kidneys,	 nerves,	 heart,	 and	 blood	 vessels.	 Several	 pathogenic	 processes	 are	 involved	 in	 the	
development	 of	 diabetes.	 These	 range	 from	 autoimmune	 destruction	 of	 the	 β-cells	 of	 the	
pancreas	with	 consequent	 insulin	 deficiency	 to	 abnormalities	 that	 result	 in	 resistance	 to	 insulin	
action.	The	basis	of	the	abnormalities	in	carbohydrate,	fat,	and	protein	metabolism	in	diabetes	is	
deficient	action	of	insulin	on	target	tissues.	Deficient	insulin	action	results	from	inadequate	insulin	
secretion	 and/or	 diminished	 tissue	 responses	 to	 insulin	 at	 one	 or	 more	 points	 in	 the	 complex	
pathways	 of	 hormone	 action.	 Impairment	 of	 insulin	 secretion	 and	 defects	 in	 insulin	 action	
frequently	coexist	in	the	same	patient,	and	it	is	often	unclear	which	abnormality,	if	either	alone,	is	
the	 primary	 cause	 of	 the	 hyperglycemia.	 Symptoms	 of	marked	 hyperglycemia	 include	 polyuria,	
polydipsia,	weight	loss,	sometimes	with	polyphagia,	and	blurred	vision.	Impairment	of	growth	and	
susceptibility	to	certain	infections	may	also	accompany	chronic	hyperglycemia.		
	
Acute,	 life-threatening	 consequences	 of	 uncontrolled	 diabetes	 are	 hyperglycemia	 with	
ketoacidosis	or	the	nonketotic	hyperosmolar	syndrome.	
	
Long-term	 complications	 of	 diabetes	 include	 retinopathy	 with	 potential	 loss	 of	 vision;	
nephropathy	leading	to	renal	failure;	peripheral	neuropathy	with	risk	of	foot	ulcers,	amputations,	
and	 Charcot	 joints;	 and	 autonomic	 neuropathy	 causing	 gastrointestinal,	 genitourinary,	 and	
cardiovascular	symptoms	and	sexual	dysfunction.	Diabetic	patients	have	an	increased	incidence	of	
atherosclerotic	cardiovascular,	peripheral	arterial,	and	cerebrovascular	disease.	Hypertension	and	
abnormalities	 of	 lipoprotein	 metabolism	 are	 often	 found	 in	 people	 with	 diabetes.	 The	 vast	
majority	of	cases	of	diabetes	fall	into	two	broad	etiopathogenetic	categories:	
- In	one	category,	 type	1	diabetes,	 the	cause	 is	an	absolute	deficiency	of	 insulin	secretion.	
Individuals	at	increased	risk	of	developing	this	type	of	diabetes	can	often	be	identified	by	
serological	 evidence	 of	 an	 autoimmune	 pathologic	 process	 occurring	 in	 the	 pancreatic	
islets	and	by	genetic	markers.	
- In	 type	 2	 diabetes,	 the	 cause	 is	 a	 combination	 of	 resistance	 to	 insulin	 action	 and	 an	
inadequate	 compensatory	 insulin	 secretory	 response.	 In	 the	 latter	 category,	 a	 degree	 of	
hyperglycemia	 sufficient	 to	 cause	 pathologic	 and	 functional	 changes	 in	 various	 target	
tissues,	 but	without	 clinical	 symptoms,	may	be	present	 for	 a	 long	period	of	 time	before	
diabetes	 is	 detected.	 During	 this	 asymptomatic	 period,	 it	 is	 possible	 to	 demonstrate	 an	
abnormality	in	carbohydrate	metabolism	by	measurement	of	plasma	glucose	in	the	fasting	
state	or	after	a	challenge	with	an	oral	glucose	 load.	The	degree	of	hyperglycemia	(if	any)	
may	 change	 over	 time,	 depending	 on	 the	 extent	 of	 the	 underlying	 disease	 process.	 A	
disease	 process	 may	 be	 present	 but	 may	 not	 have	 progressed	 far	 enough	 to	 cause	
hyperglycemia.	The	same	disease	process	can	cause	impaired	fasting	glucose	(IFG)	and/or	
impaired	glucose	tolerance	(IGT)	without	fulfilling	the	criteria	for	the	diagnosis	of	diabetes.	
In	some	individuals	with	diabetes,	adequate	glycemic	control	can	be	achieved	with	weight	
reduction,	exercise,	and/or	oral	glucoselowering	agents.	These	individuals	therefore	do	not	
require	 insulin.	 Other	 individuals	 who	 have	 some	 residual	 insulin	 secretion	 but	 require	
exogenous	 insulin	 for	 adequate	 glycemic	 control	 can	 survive	without	 it.	 Individuals	with	
extensive	β-cells	destruction	and	therefore	no	residual	insulin	secretion	require	insulin	for	
survival.	The	severity	of	the	metabolic	abnormality	can	progress,	regress,	or	stay	the	same.	
Thus,	the	degree	of	hyperglycemia	reflects	the	severity	of	the	underlying	metabolic	process	
and	its	treatment	more	than	the	nature	of	the	process	itself.	
	
2. CLASSIFICATION	 OF	 DIABETES	 MELLITUS	 AND	 OTHER	 CATEGORIES	 OF	 GLUCOSE	
REGULATION	
Assigning	a	 type	of	diabetes	 to	an	 individual	often	depends	on	the	circumstances	present	at	
the	 time	of	 diagnosis,	 and	many	diabetic	 individuals	 do	not	 easily	 fit	 into	 a	 single	 class.	 For	
example,	a	person	with	gestational	diabetes	mellitus	(GDM)	may	continue	to	be	hyperglycemic	
after	delivery	and	may	be	determined	to	have,	in	fact,	type	2	diabetes.	Alternatively,	a	person	
who	 acquires	 diabetes	 because	 of	 large	 doses	 of	 exogenous	 steroids	 may	 become	
normoglycemic	 once	 the	 glucocorticoids	 are	 discontinued,	 but	 then	 may	 develop	 diabetes	
many	years	later	after	recurrent	episodes	of	pancreatitis.	Another	example	would	be	a	person	
treated	 with	 thiazides	 who	 develops	 diabetes	 years	 later.	 Because	 thiazides	 in	 themselves	
seldom	 cause	 severe	 hyperglycemia,	 such	 individuals	 probably	 have	 type	 2	 diabetes	 that	 is	
exacerbated	by	 the	drug.	Thus,	 for	 the	clinician	and	patient,	 it	 is	 less	 important	 to	 label	 the	
particular	type	of	diabetes	than	it	is	to	understand	the	pathogenesis	of	the	hyperglycemia	and	
to	treat	it	effectively.	
	
Type	 1	 diabetes	 (β-cells	 destruction,	 usually	 leading	 to	 absolute	 insulin	 deficiency)	 Immune-
mediated	diabetes.	
This	 form	 of	 diabetes,	 which	 accounts	 for	 only	 5–10%	 of	 those	 with	 diabetes,	 previously	
encompassed	by	the	terms	insulindependent	diabetes,	type	I	diabetes,	or	juvenile-onset	diabetes,	
results	from	a	cellular-mediated	autoimmune	destruction	of	the	β-cells	of	the	pancreas.	Markers	
of	the	immune	destruction	of	the	β-cell	include	islet	cell	autoantibodies,	autoantibodies	to	insulin,	
autoantibodies	 to	 glutamic	 acid	 decarboxylase	 (GAD65),	 and	 autoantibodies	 to	 the	 tyrosine	
phosphatases	 IA-2	and	 IA-2β .	One	and	usually	more	of	 these	autoantibodies	are	present	 in	85–
90%	of	 individuals	when	 fasting	hyperglycemia	 is	 initially	detected.	Also,	 the	disease	has	 strong	
HLA	associations,	with	linkage	to	the	DQA	and	DQB	genes,	and	it	is	influenced	by	the	DRB	genes.	
These	HLA-DR/DQ	alleles	 can	be	either	predisposing	or	protective.	 In	 this	 form	of	diabetes,	 the	
rate	 of	β-cells	 destruction	 is	 quite	 variable,	 being	 rapid	 in	 some	 individuals	 (mainly	 infants	 and	
children)	and	slow	in	others	(mainly	adults).	Some	patients,	particularly	children	and	adolescents,	
may	 present	 with	 ketoacidosis	 as	 the	 first	 manifestation	 of	 the	 disease.	 Others	 have	 modest	
fasting	hyperglycemia	that	can	rapidly	change	to	severe	hyperglycemia	and/or	ketoacidosis	in	the	
presence	 of	 infection	 or	 other	 stress.	 Still	 others,	 particularly	 adults,	may	 retain	 residual	β-cell	
function	 sufficient	 to	 prevent	 ketoacidosis	 for	 many	 years;	 such	 individuals	 eventually	 become	
dependent	on	insulin	for	survival	and	are	at	risk	for	ketoacidosis.	At	this	latter	stage	of	the	disease,	
there	 is	 little	 or	 no	 insulin	 secretion,	 as	manifested	 by	 low	or	 undetectable	 levels	 of	 plasma	C-
peptide.	 Immunemediated	 diabetes	 commonly	 occurs	 in	 childhood	 and	 adolescence,	 but	 it	 can	
occur	at	any	age,	even	in	the	8th	and	9th	decades	of	life.	Autoimmune	destruction	of	β-cells	has	
multiple	genetic	predispositions	and	 is	also	related	to	environmental	 factors	 that	are	still	poorly	
defined.	 Although	 patients	 are	 rarely	 obese	 when	 they	 present	 with	 this	 type	 of	 diabetes,	 the	
presence	of	obesity	is	not	incompatible	with	the	diagnosis.	These	patients	are	also	prone	to	other	
autoimmune	disorders	such	as	Graves’	disease,	Hashimoto’s	thyroiditis,	Addison’s	disease,	vitiligo,	
celiac	 sprue,	 autoimmune	 hepatitis,	 myasthenia	 gravis,	 and	 pernicious	 anemia.	 Idiopathic	
diabetes.	Some	forms	of	type	1	diabetes	have	no	known	etiologies.	Some	of	these	patients	have	
permanent	 insulinopenia	and	are	prone	to	ketoacidosis,	but	have	no	evidence	of	autoimmunity.	
Although	only	a	minority	of	patients	with	type	1	diabetes	fall	into	this	category,	of	those	who	do,	
most	are	of	African	or	Asian	ancestry.	 Individuals	with	this	form	of	diabetes	suffer	from	episodic	
ketoacidosis	 and	 exhibit	 varying	 degrees	 of	 insulin	 deficiency	 between	 episodes.	 This	 form	 of	
diabetes	 is	 strongly	 inherited,	 lacks	 immunological	 evidence	 for	β-cell	 autoimmunity,	 and	 is	 not	
HLA	associated.	An	absolute	requirement	for	insulin	replacement	therapy	in	affected	patients	may	
come	and	go.	
	
Type	2	diabetes	(ranging	from	predominantly	 insulin	resistance	with	relative	 insulin	deficiency	
to	predominantly	an	insulin	secretory	defect	with	insulin	resistance).	
This	form	of	diabetes,	which	accounts	for	90–95%	of	those	with	diabetes,	previously	referred	to	as	
non-insulindependent	diabetes,	type	II	diabetes,	or	adult-onset	diabetes,	encompasses	individuals	
who	have	insulin	resistance	and	usually	have	relative	(rather	than	absolute)	insulin	deficiency.	At	
least	initially,	and	often	throughout	their	lifetime,	these	individuals	do	not	need	insulin	treatment	
to	 survive.	 There	 are	 probably	 many	 different	 causes	 of	 this	 form	 of	 diabetes.	 Although	 the	
specific	etiologies	are	not	known,	autoimmune	destruction	of	β-cells	does	not	occur,	and	patients	
do	not	have	any	of	 the	other	 causes	of	diabetes	 listed	above	or	below.	Most	patients	with	 this	
form	of	diabetes	are	obese,	and	obesity	 itself	causes	some	degree	of	 insulin	resistance.	Patients	
who	are	not	obese	by	 traditional	weight	 criteria	may	have	an	 increased	percentage	of	body	 fat	
distributed	predominantly	in	the	abdominal	region.	Ketoacidosis	seldom	occurs	spontaneously	in	
this	type	of	diabetes;	when	seen,	it	usually	arises	in	association	with	the	stress	of	another	illness	
such	as	infection.	This	form	of	diabetes	frequently	goes	undiagnosed	for	many	years	because	the	
hyperglycemia	develops	gradually	and	at	earlier	stages	is	often	not	severe	enough	for	the	patient	
to	notice	any	of	the	classic	symptoms	of	diabetes.	Nevertheless,	such	patients	are	at	increased	risk	
of	developing	macrovascular	and	microvascular	complications.	Whereas	patients	with	this	form	of	
diabetes	may	have	insulin	levels	that	appear	normal	or	elevated,	the	higher	blood	glucose	levels	in	
these	diabetic	patients	would	be	expected	to	result	 in	even	higher	insulin	values	had	their	β-cell	
function	 been	 normal.	 Thus,	 insulin	 secretion	 is	 defective	 in	 these	 patients	 and	 insufficient	 to	
compensate	 for	 insulin	 resistance.	 Insulin	 resistance	may	 improve	with	weight	 reduction	and/or	
pharmacological	 treatment	 of	 hyperglycemia	 but	 is	 seldom	 restored	 to	 normal.	 The	 risk	 of	
developing	this	form	of	diabetes	increases	with	age,	obesity,	and	lack	of	physical	activity.	It	occurs	
more	frequently	in	women	with	prior	GDM	and	in	individuals	with	hypertension	or	dyslipidemia,	
and	its	frequency	varies	 in	different	racial/	ethnic	subgroups.	 It	 is	often	associated	with	a	strong	
genetic	predisposition,	more	 so	 than	 is	 the	autoimmune	 form	of	 type	1	diabetes.	However,	 the	
genetics	of	this	form	of	diabetes	are	complex	and	not	clearly	defined.	
	
Other	specific	types	of	diabetes.	
Genetic	defects	of	the	β-cells.	
Several	forms	of	diabetes	are	associated	with	monogenetic	defects	in	β-cell	function.	These	forms	
of	 diabetes	 are	 frequently	 characterized	 by	 onset	 of	 hyperglycemia	 at	 an	 early	 age	 (generally	
before	age	25	years).	They	are	referred	to	as	maturityonset	diabetes	of	the	young	(MODY)	and	are	
characterized	by	impaired	insulin	secretion	with	minimal	or	no	defects	in	insulin	action.	They	are	
inherited	 in	 an	 autosomal	 dominant	 pattern.	 Abnormalities	 at	 six	 genetic	 loci	 on	 different	
chromosomes	have	been	identified	to	date.	The	most	common	form	is	associated	with	mutations	
on	 chromosome	 12	 in	 a	 hepatic	 transcription	 factor	 referred	 to	 as	 hepatocyte	 nuclear	 factor	
(HNF)-1.	A	second	form	is	associated	with	mutations	in	the	glucokinase	gene	on	chromosome	7p	
and	 results	 in	 a	 defective	 glucokinase	 molecule.	 Glucokinase	 converts	 glucose	 to	 glucose-6-
phosphate,	 the	 metabolism	 of	 which,	 in	 turn,	 stimulates	 insulin	 secretion	 by	 the	 β-cell.	 Thus,	
glucokinase	 serves	 as	 the	 “glucose	 sensor”	 for	 the	β-cell.	 Because	of	 defects	 in	 the	 glucokinase	
gene,	increased	plasma	levels	of	glucose	are	necessary	to	elicit	normal	levels	of	insulin	secretion.	
The	 less	 common	 forms	 result	 from	 mutations	 in	 other	 transcription	 factors,	 including	 HNF-4,	
HNF-1 ,	insulin	promoter	factor	(IPF)-1,	and	NeuroD1.	Point	mutations	in	mitochondrial	DNA	have	
been	 found	 to	 be	 associated	with	 diabetes	mellitus	 and	 deafness.	 The	most	 common	mutation	
occurs	 at	 position	 3243	 in	 the	 tRNA	 leucine	 gene,	 leading	 to	 an	 A-to-G	 transition.	 An	 identical	
lesion	occurs	 in	 the	MELAS	 syndrome	 (mitochondrial	myopathy,	encephalopathy,	 lactic	acidosis,	
and	 stroke-like	 syndrome);	 however,	 diabetes	 is	 not	part	 of	 this	 syndrome,	 suggesting	different	
phenotypic	expressions	of	this	genetic	lesion.	Genetic	abnormalities	that	result	in	the	inability	to	
convert	proinsulin	to	insulin	have	been	identified	in	a	few	families,	and	such	traits	are	inherited	in	
an	 autosomal	 dominant	 pattern.	 The	 resultant	 glucose	 intolerance	 is	 mild.	 Similarly,	 the	
production	 of	mutant	 insulin	molecules	with	 resultant	 impaired	 receptor	 binding	 has	 also	 been	
identified	 in	 a	 few	 families	 and	 is	 associated	 with	 an	 autosomal	 inheritance	 and	 only	 mildly	
impaired	or	even	normal	glucose	metabolism.	
	
	
	Genetic	defects	in	insulin	action.	
There	 are	 unusual	 causes	 of	 diabetes	 that	 result	 from	 genetically	 determined	 abnormalities	 of	
insulin	action.	The	metabolic	abnormalities	associated	with	mutations	of	the	insulin	receptor	may	
range	from	hyperinsulinemia	and	modest	hyperglycemia	to	severe	diabetes.	Some	individuals	with	
these	mutations	may	have	acanthosis	nigricans.	Women	may	be	virilized	and	have	enlarged,	cystic	
ovaries.	In	the	past,	this	syndrome	was	termed	type	A	insulin	resistance.	Leprechaunism	and	the	
Rabson-Mendenhall	 syndrome	 are	 two	 pediatric	 syndromes	 that	 have	 mutations	 in	 the	 insulin	
receptor	 gene	 with	 subsequent	 alterations	 in	 insulin	 receptor	 function	 and	 extreme	 insulin	
resistance.	The	 former	has	characteristic	 facial	 features	and	 is	usually	 fatal	 in	 infancy,	while	 the	
latter	is	associated	with	abnormalities	of	teeth	and	nails	and	pineal	gland	hyperplasia.	Alterations	
in	 the	 structure	 and	 function	 of	 the	 insulin	 receptor	 cannot	 be	 demonstrated	 in	 patients	 with	
insulin	 resistant	 lipoatrophic	diabetes.	 Therefore,	 it	 is	 assumed	 that	 the	 lesion(s)	must	 reside	 in	
the	postreceptor	signal	transduction	pathways.	
	
Diseases	of	the	exocrine	pancreas.	
Any	 process	 that	 diffusely	 injures	 the	 pancreas	 can	 cause	 diabetes.	 Acquired	 processes	 include	
pancreatitis,	trauma,	infection,	pancreatectomy,	and	pancreatic	carcinoma.	With	the	exception	of	
that	 caused	 by	 cancer,	 damage	 to	 the	 pancreas	 must	 be	 extensive	 for	 diabetes	 to	 occur;	
adrenocarcinomas	 that	 involve	 only	 a	 small	 portion	 of	 the	 pancreas	 have	 been	 associated	with	
diabetes.	 This	 implies	 a	 mechanism	 other	 than	 simple	 reduction	 in	 β-cells	 mass.	 If	 extensive	
enough,	cystic	fibrosis	and	hemochromatosis	will	also	damage	β-cells	and	impair	insulin	secretion.	
Fibrocalculous	pancreatopathy	may	be	accompanied	by	abdominal	pain	radiating	to	the	back	and	
pancreatic	calcifications	identified	on	X-ray	examination.	Pancreatic	fibrosis	and	calcium	stones	in	
the	exocrine	ducts	have	been	found	at	autopsy.	
	
Endocrinopathies.	
Several	 hormones	 (e.g.,	 growth	 hormone,	 cortisol,	 glucagon,	 epinephrine)	 antagonize	 insulin	
action.	Excess	amounts	of	these	hormones	(e.g.,	acromegaly,	Cushing’s	syndrome,	glucagonoma,	
pheochromocytoma,	 respectively)	 can	 cause	 diabetes.	 This	 generally	 occurs	 in	 individuals	 with	
pre-existing	defects	 in	 insulin	secretion,	and	hyperglycemia	typically	resolves	when	the	hormone	
excess	 is	 resolved.	 Somatostatinoma-	 and	 aldosteronoma-induced	 hypokalemia	 can	 cause	
diabetes,	 at	 least	 in	 part,	 by	 inhibiting	 insulin	 secretion.	 Hyperglycemia	 generally	 resolves	 after	
successful	removal	of	the	tumor.	
	
Drug-	or	chemical-induced	diabetes.	
Many	drugs	can	impair	insulin	secretion.	These	drugs	may	not	cause	diabetes	by	themselves,	but	
they	may	precipitate	diabetes	in	individuals	with	insulin	resistance.	In	such	cases,	the	classification	
is	unclear	because	the	sequence	or	relative	importance	of	β-cell	dysfunction	and	insulin	resistance	
is	 unknown.	 Certain	 toxins	 such	 as	 Vacor	 (a	 rat	 poison)	 and	 intravenous	 pentamidine	 can	
permanently	destroy	pancreatic	β-cells.	There	are	also	many	drugs	and	hormones	that	can	impair	
insulin	 action	 (i.e.	 nicotinic	 acid	 and	 glucocorticoids).	 Patients	 receiving	α-interferon	 have	 been	
reported	to	develop	diabetes	associated	with	islet	cell	antibodies	and,	in	certain	instances,	severe	
insulin	deficiency.	
	
Infections.	
Certain	 viruses	 have	 been	 associated	 with	β-cells	 destruction.	 Diabetes	 occurs	 in	 patients	 with	
congenital	rubella,	although	most	of	these	patients	have	HLA	and	immune	markers	characteristic	
of	 type	1	diabetes.	 In	addition,	 coxsackievirus	B,	 cytomegalovirus,	adenovirus,	and	mumps	have	
been	implicated	in	inducing	certain	cases	of	the	disease.	
	
Uncommon	forms	of	immune-mediated	diabetes.	
In	 this	 category,	 there	 are	 two	 known	 conditions,	 and	 others	 are	 likely	 to	 occur.	 The	 stiff-man	
syndrome	is	an	autoimmune	disorder	of	the	central	nervous	system	characterized	by	stiffness	of	
the	axial	muscles	with	painful	spasms.	Patients	usually	have	high	titers	of	the	GAD	autoantibodies,	
and	 approximately	 one-third	 will	 develop	 diabetes.	 Anti–insulin	 receptor	 antibodies	 can	 cause	
diabetes	by	binding	to	the	insulin	receptor,	thereby	blocking	the	binding	of	insulin	to	its	receptor	
in	 target	 tissues.	 However,	 in	 some	 cases,	 these	 antibodies	 can	 act	 as	 an	 insulin	 agonist	 after	
binding	to	the	receptor	and	can	thereby	cause	hypoglycemia.	Anti–insulin	receptor	antibodies	are	
occasionally	 found	 in	 patients	 with	 systemic	 lupus	 erythematosus	 and	 other	 autoimmune	
diseases.	 As	 in	 other	 states	 of	 extreme	 insulin	 resistance,	 patients	 with	 anti–insulin	 receptor	
antibodies	often	have	acanthosis	nigricans.	In	the	past,	this	syndrome	was	termed	type	B	insulin	
resistance.	
	
Other	genetic	syndromes	sometimes	associated	with	diabetes.	
Many	genetic	syndromes	are	accompanied	by	an	increased	incidence	of	diabetes	mellitus.	
These	 include	 the	chromosomal	abnormalities	of	Down’s	 syndrome,	Klinefelter’s	 syndrome,	and	
Turner’s	 syndrome.	 Wolfram’s	 syndrome	 is	 an	 autosomal	 recessive	 disorder	 characterized	 by	
insulin-deficient	diabetes	and	the	absence	of	β-cells	at	autopsy.	Additional	manifestations	include	
diabetes	insipidus,	hypogonadism,	optic	atrophy,	and	neural	deafness.		
	
Gestational	diabetes	mellitus	(GDM)	
GDM	 is	 defined	 as	 any	 degree	 of	 glucose	 intolerance	 with	 onset	 or	 first	 recognition	 during	
pregnancy.	The	definition	applies	 regardless	of	whether	 insulin	or	only	diet	modification	 is	used	
for	treatment	or	whether	the	condition	persists	after	pregnancy.	It	does	not	exclude	the	possibility	
that	 unrecognized	 glucose	 intolerance	 may	 have	 antedated	 or	 begun	 concomitantly	 with	 the	
pregnancy.	GDM	complicates	4%	of	all	pregnancies	in	the	U.S.,	resulting	in	135,000	cases	annually.	
The	prevalence	may	range	 from	1	to	14%	of	pregnancies,	depending	on	the	population	studied.	
GDM	represents	nearly	90%	of	all	pregnancies	complicated	by	diabetes.	Deterioration	of	glucose	
tolerance	occurs	normally	during	pregnancy,	particularly	in	the	3rd	trimester.		
	
Impaired	glucose	tolerance	(IGT)	and	impaired	fasting	glucose	(IFG)	
The	Expert	Committee	 (1,2)	 recognized	an	 intermediate	group	of	 subjects	whose	glucose	 levels,	
although	 not	meeting	 criteria	 for	 diabetes,	 are	 nevertheless	 too	 high	 to	 be	 considered	 normal.	
This	group	 is	defined	as	having	 fasting	plasma	glucose	 (FPG)	 levels	≥100	mg/dl	 (5.6	mmol/l)	but	
<126	mg/dl	(7.0	mmol/l)	or	2-h	values	in	the	oral	glucose	tolerance	test	(OGTT)	of	≥140	mg/dl	(7.8	
mmol/l)	but	<200	mg/dl	(11.1	mmol/l).	Thus,	the	categories	of	FPG	values	are	as	follows:	
●	FPG	<100	mg/dl	(5.6	mmol/l)	=	normal	fasting	glucose;	
●	FPG	100–125	mg/dl	(5.6–6.9	mmol/	l)	=	IFG	(impaired	fasting	glucose);	
●	 FPG	 ≥126	 mg/dl	 (7.0	 mmol/l)	 =	 provisional	 diagnosis	 of	 diabetes	 (the	 diagnosis	 must	 be	
confirmed,	as	described	below).	
The	corresponding	categories	when	the	OGTT	is	used	are	the	following:	
●	2-h	postload	glucose	<140	mg/dl	(7.8	mmol/l)	=	normal	glucose	tolerance;	
●	2-h	postload	glucose	140–199	mg/dl	(7.8–11.1	mmol/l)	=	IGT	(impaired	glucose	tolerance);	
●	2-h	postload	glucose	≥200	mg/dl	(11.1	mmol/l)	=	provisional	diagnosis	of	diabetes	(the	diagnosis	
must	be	con-	firmed,	as	described	below).	
	Patients	with	IFG	and/or	IGT	are	now	referred	to	as	having	“pre-diabetes”	indicating	the	relatively	
high	risk	for	development	of	diabetes	in	these	patients.	In	the	absence	of	pregnancy,	IFG	and	IGT	
are	 not	 clinical	 entities	 in	 their	 own	 right	 but	 rather	 risk	 factors	 for	 future	 diabetes	 as	 well	 as	
cardiovascular	disease.	 IFG	and	 IGT	are	associated	with	the	metabolic	syndrome,	which	 includes	
obesity	(especially	abdominal	or	visceral	obesity),	dyslipidemia	of	the	high-triglyceride	and/or	low-
HDL	 type,	 and	 hypertension.	 It	 is	 worth	 mentioning	 that	 medical	 nutrition	 therapy	 aimed	 at	
producing	 5–10%	 loss	 of	 body	weight,	 exercise,	 and	 certain	 pharmacological	 agents	 have	 been	
variably	demonstrated	to	prevent	or	delay	 the	development	of	diabetes	 in	people	with	 IGT;	 the	
potential	 impact	 of	 such	 interventions	 to	 reduce	 cardiovascular	 risk	 has	 not	 been	 examined	 to	
date.	Note	that	many	individuals	with	IGT	are	euglycemic	in	their	daily	lives.	Individuals	with	IFG	or	
IGT	 may	 have	 normal	 or	 near	 normal	 glycated	 hemoglobin	 levels.	 Individuals	 with	 IGT	 often	
manifest	hyperglycemia	only	when	challenged	with	the	oral	glucose	load	used	in	the	standardized	
OGTT.	
	
3.	DIAGNOSTIC	CRITERIA	FOR	DIABETES	MELLITUS	
Three	 ways	 to	 diagnose	 diabetes	 are	 possible,	 and	 each,	 in	 the	 absence	 of	 unequivocal	
hyperglycemia,	must	be	confirmed,	on	a	subsequent	day,	by	any	one	of	the	three	methods	given	
in	Table	1.	The	use	of	the	hemoglobin	A1c	(A1C)	for	the	diagnosis	of	diabetes	is	not	recommended	
at	this	time.	Diagnosis	of	GDM	The	criteria	for	abnormal	glucose	tolerance	in	pregnancy	are	those	
of	 Carpenter	 and	 Coustan.	 Recommendations	 from	 the	 American	Diabetes	 Association’s	 Fourth	
International	WorkshopConference	on	Gestational	Diabetes	Mellitus	held	in	March	1997	support	
the	use	of	the	Carpenter/Coustan	diagnostic	criteria	as	well	as	the	alternative	use	of	a	diagnostic	
75-g	 2-h	OGTT.	 These	 criteria	 are	 summarized	 below.	 Testing	 for	 gestational	 diabetes.	 Previous	
recommendations	included	screening	for	GDM	performed	in	all	pregnancies.	However,	there	are	
certain	factors	that	place	women	at	lower	risk	for	the	development	of	glucose	intolerance	during	
pregnancy,	and	it	is	likely	not	costeffective	to	screen	such	patients.	Pregnant	women	who	fulfill	all	
of	these	criteria	need	not	be	screened	for	GDM.	This	low-risk	group	comprises	women	who	
●	are	<25	years	of	age	
●	are	a	normal	body	weight	
●	have	no	family	history	(i.e.,	first-degree	relative)	of	diabetes	
●	have	no	history	of	abnormal	glucose	metabolism	
●	have	no	history	of	poor	obstetric	outcome	
●	 are	 not	members	 of	 an	 ethnic/racial	 group	with	 a	 high	prevalence	of	 diabetes	 (e.g.,	Hispanic	
American,	Native	American,	Asian	American,	African	American,	Pacific	Islander).	
Risk	 assessment	 for	 GDM	 should	 be	 undertaken	 at	 the	 first	 prenatal	 visit.	Women	with	 clinical	
characteristics	 consistent	 with	 a	 high	 risk	 of	 GDM	 (marked	 obesity,	 personal	 history	 of	 GDM,	
glycosuria,	or	a	strong	 family	history	of	diabetes)	should	undergo	glucose	testing	 (see	below)	as	
soon	 as	 feasible.	 If	 they	 are	 found	 not	 to	 have	 GDM	 at	 that	 initial	 screening,	 they	 should	 be	
retested	 between	 24	 and	 28	 weeks	 of	 gestation.	 Women	 of	 average	 risk	 should	 have	 testing	
undertaken	at	24	–28	weeks	of	gestation.	A	fasting	plasma	glucose	level	>126	mg/dl	(7.0	mmol/l)	
or	 a	 casual	 plasma	 glucose	 >200	mg/dl	 (11.1	mmol/l)	meets	 the	 threshold	 for	 the	 diagnosis	 of	
diabetes.	 In	 the	 absence	 of	 unequivocal	 hyperglycemia,	 the	 diagnosis	must	 be	 confirmed	 on	 a	
subsequent	day.	Confirmation	of	 the	diagnosis	precludes	 the	need	 for	any	glucose	challenge.	 In	
the	absence	of	this	degree	of	hyperglycemia,	evaluation	for	GDM	in	women	with	average	or	high-
risk	characteristics	should	follow	one	of	two	approaches.	
One-step	approach:	perform	a	diagnostic	OGTT	without	prior	plasma	or	serum	glucose	screening.	
The	 one-step	 approach	 may	 be	 cost-effective	 in	 high-risk	 patients	 or	 populations	 (e.g.,	 some	
NativeAmerican	groups).	
Two-step	 approach:	 perform	 an	 initial	 screening	 by	 measuring	 the	 plasma	 or	 serum	 glucose	
concentration	 1	 h	 after	 a	 50-g	 oral	 glucose	 load	 (glucose	 challenge	 test	 [GCT])	 and	 perform	 a	
diagnostic	 OGTT	 on	 that	 subset	 of	 women	 exceeding	 the	 glucose	 threshold	 value	 on	 the	 GCT.	
When	the	two-step	approach	is	used,	a	glucose	threshold	value	>140	mg/dl	(7.8	mmol/l)	identifies	
80%	 of	women	with	GDM,	 and	 the	 yield	 is	 further	 increased	 to	 90%	 by	 using	 a	 cutoff	 of	 >130	
mg/dl	(7.2	mmol/l).	With	either	approach,	the	diagnosis	of	GDM	is	based	on	an	OGTT.	Diagnostic	
criteria	 for	 the	 100-g	 OGTT	 are	 derived	 from	 the	 original	 work	 of	 O’Sullivan	 and	 Mahan	 (4)	
modified	 by	 Carpenter	 and	 Coustan	 (3)	 and	 are	 shown	 in	 the	 top	 of	 Table	 3.	 Alternatively,	 the	
diagnosis	 can	 be	 made	 using	 a	 75-g	 glucose	 load	 and	 the	 glucose	 threshold	 values	 listed	 for	
fasting,	 1	 h,	 and	2	h	 (Table	 2,	 bottom);	 however,	 this	 test	 is	 not	 as	well	 validated	 as	 the	 100-g	
OGTT.	
	
	
	
	
		
Table	1.	Criteria	for	the	diagnosis	of	diabetes	mellitus	
1. Symptoms	of	diabetes	plus	casual	plasma	glucose	concentration	>200	mg/dl	(11.1	mmol/	l).	Casual	is	
defined	as	any	time	of	day	without	regard	to	time	since	last	meal.	The	classic	symptoms	of	diabetes	
include	polyuria,	polydipsia,	and	unexplained	weight	loss.	
2. or	2.	FPG	<126	mg/dl	(7.0	mmol/l).	Fasting	is	defined	as	no	caloric	intake	for	at	least	8	h.	
3. or	3.	2-h	postload	glucose	>200	mg/dl	(11.1	mmol/l)	during	an	OGTT.	The	test	should	be	performed	
as	 described	 by	WHO,	 using	 a	 glucose	 load	 containing	 the	 equivalent	 of	 75	 g	 anhydrous	 glucose	
dissolved	in	water.	In	the	absence	of	unequivocal	hyperglycemia,	these	criteria	should	be	confirmed	
by	 repeat	 testing	 on	 a	 different	 day.	 The	 third	measure	 (OGTT)	 is	 not	 recommended	 for	 routine	
clinical	use.		
Diagnosis	and	Classification	DIABETES	CARE,	VOLUME	27,	SUPPLEMENT	1,	JANUARY	2004		
	
THE	IMPACT	OF	DM	ON	THE	HEART:	DIABETIC	CARDIOMYOPATHY	
It	has	been	well	established	the	association	of	diabetes	with	hypertension,	obesity	and	coronary	
heart	 disease	 and	 predisposes	 diabetic	 subjects	 to	 heart	 failure	 (HF).	 This	 has	 been	 linked	 to	
duration	of	diabetes	and	the	extent	of	glycemic	control.	Cardiovascular	morbidity	and	mortality	in	
diabetes	are	strikingly	high	with	a	reduction	in	life	expectancy.	
It	has	been	recently	shown	that	individuals	in	their	sixties	who	have	a	combination	of	diabetes	and	
heart	disease	have	an	average	reduction	 in	 life	expectancy	of	about	15	years.	Four	decades	ago	
the	 Framingham	 study	 firmly	 established	 the	 epidemiologic	 link	 between	 diabetes	 and	 HF,	
showing	 that	 diabetes	 predicted	 heart	 failure	 independent	 of	 hypertension,	 age,	 obesity,	
dyslipidemia	and	coronary	disease.	
It	is	now	recognized	that	in	addition	to	accelerating	and	worsening	the	consequences	of	coronary	
artery	disease	and	hypertension,	diabetes	also	has	a	direct	effect	on	the	myocardium,	placing	the	
diabetic	subject	at	an	increased	risk	of	developing	heart	failure.	
Diabetes	increases	the	odds	of	a	non-ischemic	dilated	cardiomyopathy	(odds	ratio:	1.75;	95%	CI:	
1.71-1.79),	which	has	been	associated	with	increased	myocardial	stiffness.	This	entity	of	a	unique	
diabetic	 cardiomyopathy	 (DMCMO)	 was	 originally	 proposed	 by	 Lundbeek	 and	 subsequently	
confirmed	at	autopsy	by	Rubler	et	al	 in	1972	in	four	diabetic	patients	who	presented	with	heart	
failure	(HF)	and	showed	no	evidence	of	hypertension	(HT),	CAD,	or	valvular	disease.	Rubler	found	
evidence	of	myocardial	hypertrophy,	 fibrosis,	and	microvascular	changes	 in	keeping	with	dilated	
cardiomyopathy.	The	development	of	myocardial	dysfunction	 in	diabetes	has	been	attributed	to	
the	 effects	 of	 lipotoxicity,	 microvascular	 AGEs	 deposition,	 microvascular	 rarefaction,	 and	
autoimmunity,	 all	 of	 which	 contribute	 to	 produce	 myocardial	 fibrosis	 and/or	 myocardial	
hypertrophy,	the	hallmarks	of	DMCMO	that	are	described	below	(Table	2).	
Table	2.	Contribution	of	pathophysiological	mechanisms	to	the	phenotypes	of	diabetic	cardiomyopathy	
Metabolic	overload	effects	 HFPEF	 HFREF	
Insulin	resistance/hyperinsulinemia	 +++	 +	
Hyperglycemia	 +++	 +	
Lipotoxicity	&	oxidative	stress	 +++	 +	
AGEs	deposition	 +++	 +++	
Microvascular	rarefaction		 +++	 +++	
Autoimmunity		 -	 +++	
Structural	changes	 Functional	effects	
Stimulus	to	ventricular	remodeling	 Endothelial	dysfunction	 Autoimmune	cell	death	
Effects	of	microvascular	dysfunction	 Low	NO	availability	 Hypoxic	damage	
Cardiomyocyte	changes	 Hypertrophy	&	stiffening	 Stiffening	&	apoptosis	
Myocardial	matrix	changes	 AGEs	+reactive	fibrosis	 AGEs	+	replacement	fibrosis	
		 Diastolic	dysfunction	 Systolic	dysfunction	
	
	
	
	
	
Diabetic	cardiomyopathy	has	been	previously	differentiated	into	two	phenotypes:	
- restrictive	or	heart	failure	with	preserved	left	ventricular	ejection	fraction	(HFPEF)	
- dilated	or	heart	failure	with	impaired	or	reduced	left	ventricular	ejection	fraction	(HFREF).	
The	phenotype-specific	pathophysiological	mechanisms	for	the	DCM	phenotypes	proposed	for	left	
ventricular	 (LV)	 remodeling	 and	 dysfunction	 consist	 of	 coronary	 microvascular	 endothelial	
dysfunction	 and	 cardiomyocyte	 cell	 death	 for	 HFPEF	 and	 HFREF,	 respectively.	 Similarly,	 the	
preference	of	endothelial	or	cardiomyocyte	cell	compartments	 in	DM	patients	could	explain	 the	
development	of	DCM	into	two	subtypes,	restrictive/HFPEF	or	dilated/HFREF	phenotypes.	Diabetes	
mellitus-induced	 metabolic	 derangements	 such	 as	 hyperglycemia,	 lipotoxicity,	 and	
hyperinsulinemia	 favor	 development	 of	 DCM	 with	 the	 restrictive/HFPEF	 type,	 which	 is	 more	
prevalent	 in	 obesity.	 In	 contrast,	 autoimmunity	 predisposes	 to	 the	 dilated/HFREF	 phenotype,	
which	 manifests	 itself	 more	 in	 type	 1	 DM.	 Finally,	 coronary	 microvascular	 rarefaction	 and	
advanced	 glycation	 end	 products	 (AGEs)	 deposition	 are	 relevant	 pathognomic	 abnormalities	 in	
both	phenotypes.	
1.	Pathogenetic	mechanisms	of	myocardial	dysfunction	in	diabetes	
Role	of	hyperglycemia	
Hyperglycemia	 (Figure	 1)	 increases	 the	 level	 of	 free	 fatty	 acids	 and	 growth	 factors	 in	 the	
myocardium,	and	causes	abnormalities	in	substrate	supply	and	utilization.	Furthermore,	it	is	toxic	
to	the	endothelial	cell,	causes	mitochondrial	damage	and	induces	oxidative	stress	and	the	release	
of	superoxides,	leading	to	abnormal	gene	expression,	impaired	production	of	nitric	oxide	(NO)	and	
reduced	distensibility	of	cardiomyocytes.	
Hyperglycemia	activates	the	renin-angiotensin	system	in	myocardial	cells	(Figure	1)	leading	to	cell	
growth	 and	 cardiac	 hypertrophy	 and	 these	 damaging	 effects	 can	 be	 further	 aggravated	 by	
oxidative	 stress.	 In	 addition,	 it	 stimulates	 collagen	 production	 and	 crosslinking	 as	 well	 as	 the	
production	and	deposition	of	non-enzymatic	formation	of	advanced	glycation	end-products	(AGEs)	
in	 the	 coronary	 microvasculature	 and	 the	 myocardial	 interstitium.	 AGEs	 trigger	 vascular	
inflammation,	 lower	myocardial	 NO	 bioavailability	 and	 contribute	 to	 concentric	 LV	 remodeling.	
AGEs-induced	crosslinking	in	collagen	and	elastin	and	result	in	increased	myocardial	stiffness	and	
impaired	 cardiac	 relaxation	 in	 the	 diabetic	 heart	 that	 has	 been	 correlated	 with	 tissue	 Doppler	
indices	of	diastolic	dysfunction.		
Figure	1.	Cardiometabolic	mechanisms	in	myocyte	injury.	
	
	
Insulin	resistance/hyperinsulinemia	
Insulin	resistance	(IR)	affects	a	number	of	signaling	pathways,	causing	cardiomyocyte	hypertrophy,	
reactive	 interstitial	 fibrosis	 and	 expression	 of	 myocardial	 titin,	 all	 of	 which	 contribute	 to	 the	
reduction	 in	 cardiomyocyte	distensibility.	 Central	 obesity	 (associated	with	 IR)	 and	microvascular	
rarefaction	cause	the	release	of	proinflammatory	cytokines	and	the	generation	of	reactive	oxygen	
species	(ROS),	leading	to	an	inflammatory	state	in	the	coronary	microvasculature	with	a	reduction	
in	 nitric	 oxide	 (NO)	 bioavailability,	 increased	 vessel	 permeability	 and	 programmed	 cell	 death	
(apoptosis).	 This	 coronary	 microvascular	 endothelial	 dysfunction	 is	 thought	 to	 drive	 the	
development	 of	 myocyte	 hypertrophy	 with	 concentric	 remodeling	 and	 myocardial	 stiffening	
resulting	in	LV	diastolic	dysfunction.	
Lipotoxicity	and	mitochondrial	dysfunction	
Insulin	resistance	results	 in	a	reduction	of	myocardial	energy	supply	due	to	changes	 in	substrate	
utilization	 from	glucose	 to	 free	 fatty	acids.	 It	 impairs	myocardial	glucose	utilization	and	 leads	 to	
excess	 fatty	 acid	uptake	 into	 cardiomyocytes	 and	eventually	 induces	mitochondrial	 dysfunction,	
reduction	in	ATP	availability	and	eventual	cell	death	(lipotoxicity).	The	defect	in	myocardial	energy	
production	impairs	myocyte	contractile	function,	manifesting	initially	as	diastolic	function.	Excess	
myocardial	 triglyceride	 content	 (myocardial	 steatosis)	 is	 demonstrable	 on	 proton-MR	
spectroscopy	and	has	been	correlated	with	echocardiographic	left	ventricular	diastolic	dysfunction	
as	well	as	with	longitudinal	strain	measurements.	
Impaired	coronary	flow	reserve	in	diabetes	
Several	 factors:	 reduced	 NO	 production,	 AGEs-	 mediated	 stiffening	 of	 coronary	 media,	 and	
perivascular	 fibrosis,	 contribute	 to	 a	 reduction	 in	 coronary	 flow	 reserve.	 In	 addition,	
cardiomyocyte	 hypertrophy	 is	 associated	 with	 a	 reduction	 in	 capillary	 density	 (microvascular	
rarefaction)	that	leads	to	impaired	myocardial	perfusion,	lowers	NO	bioavailability	and	contributes	
to	myocardial	stiffness	that	is	typical	of	diastolic	dysfunction.	Tissue	hypoxia	results	in	the	further	
release	 of	 ROS	 leading	 to	 myocyte	 cell	 death	 (apoptosis)	 and	 a	 decline	 in	 systolic	 function	
accompanied	by	remodeling	with	ventricular	dilatation.	
Microvascular	disease	and	ischemia	
Microangiopathy,	characterized	by	thickening	of	the	capillary	basement	membrane	and	the	media	
of	the	arteriole,	and	associated	with	perivascular	fibrosis,	has	been	observed	in	autopsy	samples	
of	diabetic	patients.	Microaneurysms	and	spiral	deformation	of	microvessels	in	the	myocardium	of	
type	2	DM,	similar	to	retinal	vascular	changes	of	diabetes,	have	also	been	described.	It	has	been	
shown	 that	 expression	 of	 vascular	 endothelial	 cell	 growth	 factor	 (VEGF)	 in	 the	 heart	 is	
downregulated	in	diabetes	and	that	this	downregulation	is	closely	associated	with	the	reduction	in	
capillary	density,	apoptosis	of	endothelial	cells	and	interstitial	fibrosis.	
The	microangiopathy	in	diabetes	explains	why	microalbuminuria/proteinuria	is	not	only	associated	
with	nephropathy,	but	with	widespread	microvascular	disease,	 including	the	heart.	 In	 the	heart,	
diabetic	autonomic	neuropathy	contributes	to	impaired	autoregulation	and	lack	of	flow	reserve,	a	
factor	 that	may	account	 for	 increased	 rates	of	 sudden	 cardiac	death	as	well	 as	 a	higher	overall	
cardiovascular	mortality	rate	in	diabetic	patients.	
Autoimmunity	
In	type	1	DM	subjects,	cardiac	myosin	autoantibody	and	troponin	T	release	are	thought	to	trigger	
an	immune	response	leading	to	myocyte	cell	death	and	replacement	fibrosis.	It	has	been	proposed	
that	 this	 immune	 response,	 combined	 with	 the	 effects	 of	 worsening	 tissue	 hypoxia	 described	
above,	 probably	 provide	 the	 stimulus	 to	 the	 development	 of	 eccentric	 ventricular	 remodeling,	
resulting	 in	 ventricular	 dilatation	 and	 systolic	 dysfunction	 leading	 to	 the	 picture	 of	 dilated	
cardiomyopathy	that	has	been	described	in	type	1DM.	
2.	Development	of	myocardial	dysfunction	
As	 explained	 above,	 excess	 chronic	 oxidative	 stress	 produced	 by	 the	 release	 of	 ROS	 from	 the	
mitochondria	and	from	proinflammatory	cytokines	and	leucocytes,	cause	direct	damage	to	plasma	
membrane	 cell	 organelles	 leading	 to	 myocardial	 damage.	 This	 may	 account	 for	 the	 increased	
oxidative	 injury	 resulting	 in	 the	 excessive	morbidity	 and	mortality	 after	myocardial	 infarction	 in	
patients	 with	 diabetes	 when	 compared	 to	 patients	 without	 diabetes.	 Oxidative	 stress	 is	 the	
unifying	 factor	 in	 the	 development	 of	 diabetes-related	 cardiac	 complications,	 including	
atherosclerosis	(Figure	1).	
Myocardial	 damage	 in	 the	absence	of	 epicardial	 coronary	disease	 (macrovascular)	 is	most	 likely	
related	to	microvascular	dysfunction,	leading	to	diabetic	cardiomyopathy	(DMCMO).	
Recent	 evidence	 has	 shown	 that	 insulin	 resistance-induced	 arterial	 stiffness	 in	 normotensive	
subjects	contributes	 to	diastolic	dysfunction	 independent	of	age,	blood	pressure	and	body	mass	
index.	Together	with	activation	of	the	sympathetic	nervous	system,	the	increase	in	afterload	and	
impaired	ventricular-vascular	coupling	as	a	result	of	arterial	stiffness	 increase	 likelihood	of	heart	
failure	development	in	these	subjects.	
Based	on	the	fact	that	subjects	with	diastolic	dysfunction	have	more	LV	hypertrophy	and	stiffness	
(attributed	to	AGEs	deposition	and	stiff	cardiomyocytes),	while	subjects	with	systolic	dysfunction	
have	a	dilated	left	ventricle	(following	cardiomyocyte	cell	death	and	replacement	fibrosis),	a	new	
model	 of	 diabetic	 cardiomyopathy	 has	 been	 proposed.	 In	 a	 recent	 review	 Seferovic	 and	 Paulus	
proposed	that	the	deposition	of	AGEs	in	the	myocardium	and	coronary	microvascular	rarefaction	
contribute	 to	 both	 diastolic	 and	 systolic	 dysfunction.	 Hyperglycemia,	 lipotoxicity,	 and	
hyperinsulinemia	lead	to	myocyte	hypertrophy,	increased	diastolic	stiffness	and	the	development	
of	the	restrictive/HFPEF	phenotype,	typical	in	obese	type	2	DM	patients	(Figure	1).	Autoimmunity	
with	myocyte	cell	death	leads	to	the	dilated/HFREF	phenotype	that	is	more	prevalent	in	type	1	DM	
patients.	 In	 this	 model,	 more	 selective	 involvement	 of	 endothelial	 cells	 in	 the	 coronary	
microvasculature	drives	the	progression	to	diastolic	dysfunction,	while	cardiomyocyte	damage	and	
ensuing	myocyte	loss	trigger	eccentric	remodeling	and	decline	in	systolic	function.		
Changes	in	biventricular	cardiac	function	in	diabetic	cardiomyopathy	are	summarized	in	Figure	2.	
Figure	2.	Cardiac	Dysfunction	in	diabetic	cardiomyopathy	
	
3.	Epidemiology	
Because	 of	 the	 structural	 and	 functional	 changes	 that	 occur	 in	 DMCMO,	 subjects	 develop	
functional	changes	early	in	the	course	of	their	disease.	Diastolic	dysfunction	is	the	most	frequent	
echocardiographic	 finding	 in	 both	 type	 1	 DM	 and	 type	 2	 DM	 patients	 and	 precedes	 the	
development	of	symptoms.	The	prevalence	of	asymptomatic	diastolic	abnormalities	detected	on	
TDI	in	a	population-based	study	is	high	(23%)	with	over	a	third	developing	heart	failure	at	5	years.	
In	the	early	stages	of	type	1	DM,	subclinical	myocardial	dysfunction	is	frequent,	but	clinical	signs	of	
heart	failure	are	infrequent	and	developed	in	3.7%	of	subjects	over	a	12-year	follow-up	period	in	
one	study.	Subjects	who	developed	heart	failure	were	older	and	had	a	longer	duration	of	diabetes	
(35±9	 years);	 they	 had	 higher	 blood	 pressure	 and	 a	 higher	 prevalence	 of	 albuminuria	 and	
retinopathy	than	those	without	heart	 failure.	Diabetic	patients	with	microvascular	complications	
showed	 the	 strongest	 association	 with	 cardiomyopathy	 and	 this	 relationship	 paralleled	 the	
duration	 and	 severity	 of	 hyperglycemia.	 These	 findings	 have	 been	 confirmed	 in	 a	 recent	 large	
case-controlled	 study	 from	 the	Swedish	national	 registry	 that	 showed	a	 fourfold	 increase	 in	 the	
risk	of	heart	failure	in	type	1	DM,	especially	 in	subjects	with	poor	glycemic	control	and	impaired	
renal	function.	
4.	Clinical	markers	and	implications	for	treatment	
Asymptomatic	 diastolic	 dysfunction	 offers	 an	 opportunity	 for	 the	 primary	 prevention	 of	 heart	
failure	 in	 at-risk	 diabetic	 subjects	 if	 changes	 can	 be	 detected	 early	 and	 appropriate	 therapy	
instituted.	 Since	 there	 is	 little	 evidence	 to	 support	 the	use	of	 biomarkers	 in	 detecting	 the	early	
stages	 of	 DMCMO,	 a	 strategy	 of	 screening	 asymptomatic	 diabetic	 subjects	 for	 impaired	 LV	
function	with	natriuretic	peptides	 is	 not	 recommended.	 It	 is	 suggested	 that	diabetic	 subjects	 at	
risk	 of	 developing	 DMCMO	 (such	 as	 those	with	 atrial	 fibrillation,	microalbuminuria/proteinuria,	
autonomic	 neuropathy,	 retinopathy,	metabolic	 syndrome)	 should	undergo	non-invasive	 imaging	
using	tissue	Doppler	imaging	and	strain	rate	imaging	as	well	as	magnetic	resonance	spectroscopy,	
to	enable	early	detection	of	DMCMO.	
Subclinical	changes	of	diastolic	dysfunction	has	been	demonstrated	across	the	spectrum	of	IR	and	
may	present	before	the	onset	of	diabetes,	presenting	an	even	larger	disease	burden	for	primary	
prevention	 of	 heart	 failure	 in	 diabetes.	 There	 is	 evidence	 that	 glycemic	 control	 and	 lifestyle	
measures	 started	 earlier	 in	 the	 course	 of	 the	 IR	 spectrum	 (early	 diabetes,	 prediabetes	 and	
metabolic	 syndrome)	 could	 address	 the	metabolic	milieu	 before	 they	 have	 become	 established	
and	 may	 be	 beneficial.	 In	 this	 respect	 the	 Diabetes	 Control	 and	 Complications	 Trial	
(DCCT)/Epidemiology	 of	 Diabetes	 Interventions	 and	 Complications	 (EDIC)	 study	 has	 shown	 that	
intensive	 treatment	 of	 hyperglycemia,	 targeting	 glycated	 hemoglobin	 levels	 below	 7%,	 when	
initiated	early	in	patients	with	short	duration	of	diabetes	and	low	cardiovascular	risk,	results	in	a	
significant	42%	reduction	of	cardiovascular	events	in	the	long	term.	
The	diagnosis	of	diabetic	cardiomyopathy	may	be	suspected	when	myocardial	disease	in	patients	
with	 diabetes	 cannot	 be	 attributed	 to	 any	 other	 known	 cardiovascular	 disease.	 Metabolic	 and	
microvascular	 mechanisms	 contribute	 to	 the	 pathogenesis.	 At	 a	 subcellular	 level	 in	 the	
mitochondrion,	oxidative	stress,	coupled	with	loss	of	normal	microvessels	and	remodeling	of	the	
extracellular	 matrix,	 lead	 to	 an	 inflammatory	 state	 with	 decline	 in	 cardiomyocyte	 contractile	
function.	 The	 disease	 course	 consists	 of	 a	 hidden	 subclinical	 period,	 during	 which	 endothelial	
dysfunction	 drives	 the	 cellular	 and	 matrix	 changes	 that	 result	 in	 diastolic	 stiffness,	 while	
autoimmune	responses	result	in	myocyte	loss	and	decline	in	systolic	function.	
Subjects	at	risk	of	DMCMO	are	those	with	a	long	duration	of	poorly	controlled	diabetes,	evidence	
of	microvascular	disease	elsewhere,	atrial	fibrillation	and	those	with	markers	of	insulin	resistance	
such	as	central	obesity	and	metabolic	syndrome.	
	
5.	Diagnostic	approach	
Diagnosis	 of	 DCM	 requires	 impairment	 of	 the	 glucose	metabolism	 and	 a	 thorough	 approach	 to	
exclude	 other	 causes	 of	 ventricular	 dysfunction	 such	 as	 coronary,	 valvular,	 hypertensive,	 or	
congenital	 heart	 disease	 and	 infections	 such	 as	 viral	 myocarditis	 or	 toxins-induced,	 familial	 or	
infiltrative	 cardiomyopathies.	 Although	 the	 chief	 cause	 of	 DCM	 is	 diabetes,	 the	 following	 risk	
factors	which	might	exacerbate	DCM	need	special	attention:	obesity,	chronic	high	blood	glucose,	
high	blood	pressure,	dyslipidemia,	smoking	and	alcohol	consumption.	
A	 relevant	 diagnostic	 approach	 should	 be	 employed	 to	 diagnose	 DCM,	 which	 should	 include	 a	
thorough	 history	 and	 a	 proper	 physical	 examination:	 relevant	 investigative	 approach	 including	
urine	analysis	to	test	for	the	presence	of	proteinuria,	stress	test,	chest	X-ray,	electrocardiography	
and	echocardiography	(Table	3).	 Invasive	measures	should	also	be	considered	in	some	situations	
including	 myocardial	 biopsy,	 cardiac	 catheterization	 to	 evaluate	 cardiac	 chamber	 blood	 flow,	
pressures	and	coronary	blood	flow.	
	
	
	
	
	
	Table	3.	Diagnostic	approaches	employed	in	the	diagnosis	of	DCM.	
Diagnostic	tool	 Parameters	and	implications	
Clinical	 • History	of	DM,	DCM	and	family	history	of	diabetes.	
• Physical	examination,	evaluation	of	symptoms	and	complications	
Biochemistry	 • Urine,	for	proteinuria	
• Serum	 aminoterminal	 propeptide	 of	 type	 I	 and	 type	 III	 collagens,	 and	
carboxyterminal	telopeptide	of	type	I	collagen	
• B-natriuretic	 peptide	 (BNP),	 for	 increased	 ventricular	 pressure	 or	 heart	
failure	
Transthoracic	
echocardiography	
• Transmitral	Doppler	analysis,	for	left	ventricular	mass	and	diameter	
• Pulmonary	venous	blood	flow,	for	diastolic	dysfunction	
• Color	M-mode,	for	diastolic	dysfunction	
• TDI,		decreased	tissue	velocities	for	both	diastolic	and	systolic	dysfunction	
• TDI,	strain	and	strain	rate,	for	systolic	and	diastolic	dysfunction	
Magnetic	resonance	imaging	
		
• MRI,	for	left	ventricular	mass	and	diameter	
• Late	gadolinium	enhancement	MRI,	for	diastolic	and	systolic	dysfunction	
• Magnetic	 resonance	 spectroscopy,	 for	 myocardial	 fibrosis,	 triglyceride	
content	and	myocardial	phosphocreatine	to	ATP	ratio	
SPECT	 • Flow	limitation	and	sarcolemmal	membrane	integrity	
• G-SPECT,	differentiate	ischemic	from	non-ischemic	cardiomyopathy,	assess	
both	myocardial	perfusion	and	ventricular	function	
• Quantitative	myocardial	 perfusion	 SPECT,	myocardial	 and	 coronary	 artery	
disease	
PET	 Radiotracer	kinetics,	quantitative	assessment	of	myocardial	blood	flow	
5.1	Echocardiography	
Although	2D-TTE	is	cheap	and	easily	accessible,	it	is	hampered	by	the	inability	to	detect	the	subtle	
features	of	myocardial	dysfunction	in	DM.	Newer	technologies,	such	as	TDI,	look	promising	as	they	
apply	 a	 high-velocity	 low-amplitude	 filter	 to	 the	 myocardium,	 enabling	 an	 assessment	 of	
myocardial	 tissue	 velocities	 with	 relative	 ease.	 The	 advantage	 of	 TDI	 over	 standard	 Doppler	
echocardiographic	 indices	 is	 that	 the	results	are	 independent	of	changes	 in	ventricular	pre-load.	
However,	 TDI	 is	 unable	 to	differentiate	between	active	 contraction	 and	passive	movement	of	 a	
myocardial	segment.	
Speckle	tracking	echocardiography	(STE)	
Strain	and	strain	rate	echocardiography	is	a	unique	technique	for	assessing	myocardial	systolic	and	
diastolic	 function.	 STE	 has	 improved	 the	 quantitative	 assessment	 of	 regional	 or	 segmental	wall	
motion	and	also	the	accuracy	and	reproducibility	of	test	readings.	STE	is	a	new	advanced	imaging	
tool	 which	 is	 highly	 sensitive	 and	 reproducible	 to	 evaluate	 subtle	 features	 of	 ventricular	
myocardial	 dysfunction.	 Changes	 in	 ventricular	 systolic	 strain	 and	 strain	 rate	 have	 the	potential	
ability	to	discriminate	between	different	myocardial	viability	states.	Measurement	of	the	diastolic	
rate	of	deformation	can	differentiate	physiological	from	pathological	hypertrophy	and	restrictive	
from	constrictive	cardiomyopathy.	
Contrast	echocardiography	
Contrast	 echocardiography	 is	 useful	 in	 current	 clinical	 practice	 as	 proper	 delineation	 of	 the	
endocardial	border	observed	after	contrast	administration	increases	the	clarity	of	the	images	and	
improves	 the	 results	 provided	 by	 the	 algorithms	 orientated	 to	 the	 assessment	 of	 ventricular	
motion.	Moreover,	direct	assessment	of	myocardial	blood	flow	and	flow	reserve	 is	possible	with	
contrast	 echocardiography,	 as	 microbubble	 contrast	 agents	 remain	 entirely	 within	 the	
intravascular	space.	In	any	myocardial	segment,	contrast	echocardiography	denotes	the	status	of	
microvascular	 perfusion	 within	 that	 region,	 which	 is	 important	 in	 patients	 with	 long-standing	
diabetes.	Contrast	LV	opacification	allows	more	accurate	measurements	of	LV	size	and	mass,	and	
myocardial	contrast	echocardiography	could	provide	an	alternative	non-invasive	imaging	method	
to	evaluate	the	coronary	anatomy	to	exclude	CAD.	
Three-dimensional	echocardiography	
Real-time	three-dimensional	echocardiography	is	used	in	conjunction	with	strain	rates	for	further	
evaluation	 of	 regional	 LV	 systolic	 and	 diastolic	 function.	 A	 similar	 approach	 could	 be	 used	 to	
evaluate	LV	and	RV	function	in	patients	with	long-standing	DM	or	DCM.	
	
5.2	Computed	tomography	
Similarly,	 coronary	 artery	 calcification	 (CAC)	 can	 increase	 significantly	 in	 asymptomatic	 patients	
with	 long-standing	 type	 2	 DM	 compared	 with	 non-diabetic	 subjects.	 The	 CAC	 score,	 derived	
originally	 from	electron-beam	computed	tomography	(CT)	and	more	recently	 from	multislice	CT,	
correlates	 strongly	with	 the	 presence	 and	 severity	 of	 histological	 and	 angiographic	 evidence	 of	
coronary	 atherosclerosis	 and	 conventional	 coronary	 heart	 disease	 risk	 factors,	 in	 particular	 C-
reactive	protein,	reflecting	stable	and	unstable	plaques.	
5.3	Magnetic	resonance	
Cardiac	 MRI	 has	 recently	 emerged	 as	 a	 useful	 imaging	 tool	 for	 structural	 and	 functional	
myocardium	disorders.	It	is	also	an	important	non-invasive	modality	to	detect	diastolic	dysfunction	
and	myocardial	steatosis	in	DM	and	other	pathological	myocardial	disease.	
In	 particular	 cardiac	MR	 enable	 to	 assess	 the	 presence	 of	 myocardial	 fibrosis	 using	 direct	 and	
indirect	technique:	
1)	Direct:	LGE	and	T1	mapping	
2)	Indirect:	Tagging	and	Feature	tracking	
Late-Gadolinium	Enhancement	(LGE)	
Fibrotic	 areas	 within	 myocardium	 are	 identified	 on	 CMR	 by	 a	 semiquantitative	 analysis	 of	 the	
myocardial	signal	intensity	(SI)	10-15	minutes	after	injection	of	Gd	on	Inversion	Recovery	Gradient	
Echo	T1-weighted	images).		After	nulling	the	signal	of	healthy	myocardium	by	an	inversion	pulse,	
the	fibrosis	appears	on	the	LGE	images	as	hyperintense	myocardial	regions	distinguishable	by	non-
injured,	healthy,	remote	myocardium	(Figure	3).	
	
	
	
	
	
	Figure	3.	Gadolinium	in	healthy	and	pathological	myocardium	
	
This	technique	is	very	effective	in	the	localization	and	definition	of	focal	fibrosis	and	it	enables	to	
discriminate	ischemic	from	non-ischemic	disease	(Figure	4).		
	
	
	
	
	
	
	
	
	
	
	
	
Figure	4.	LGE	in	ischemic	and	non-ischemic	disease	
	
This	 technique	 it	 does	 not	 work	 equally	 in	 the	 detection	 of	 diffuse	 fibrosis	 is	 burden	 by	 the	
operator	dependence.	
T1	mapping	
This	 technique	 allow	 signal	 quantification	 by	 the	 use	 of	 standardized	 reproducible	 T1	 and	 T2	
values	(expressed	in	milliseconds),	which	appears	to	be	more	robust	than	qualitative	assessment	
of	signal	intensity.	
Nonenhanced	T1	Mapping		
All	 tissues	have	 inherent	T1	relaxation	times	that	are	based	on	a	composite	of	their	cellular	and	
interstitial	components	(water,	protein,	 fat,	and	 iron	content).	At	a	fixed	magnetic	field	strength	
and	 in	the	absence	of	exogenous	contrast	agent	(i.e.	gadolinium	chelate),	 the	native	T1	value	of	
normal	 tissue	 falls	within	a	predictable	 range	 (at	1.5	T,	normal	myocardium	has	a	T1	 relaxation	
time	 of	 940–1000	msec).	Whereas	 qualitative	 sequences	 rely	 on	 the	 use	 of	 arbitrary	 signal	 in-
tensity	scales	for	T1	and	T2	values	that	have	inter-patient	and	inter-image	variability,	myocardial	
mapping	offers	the	potential	to	produce	images	that	have	standardized,	reproducible	scales	simi-
lar	to	the	attenuation	values	used	at	computed	tomography.		
Mapping	sequences	employ	different	techniques	(MOLLI,	ShMOLLI,	SASHA,	SAPHIRE	sequences)	to	
acquire	a	series	of	 images	at	various	 inversion	times,	from	which	a	T1	recovery	curve	is	derived.	
The	 result	 is	 a	 T1	map,	 a	 parametric	 image	 that	 displays	 the	 T1	 relaxation	 values	 pixel	 by	 pixel	
(Figure	5).	
	
Figure	5.	Native	T1	mapping:	a)	 same	plane	acquired	with	different	T1	and	native	T1	map;	b)	Graph	of	a	
curve-fitting	analysis	for	a	single	pixel.	(Courtesy	of	Hamlin	S	et	al;	Radiographics	2014)	
	
	
These	maps	are	commonly	displayed	using	color	to	aid	in	visual	interpretation.	Regions	of	interest	
can	be	drawn	to	assess	a	larger	area	of	the	myocardium.		
Native	myocardial	T1	relaxation	times	vary	by	magnetic	field	strength	(3-T	magnets	result	in	longer	
native	 T1	 times),	 equipment	 manufacturer,	 and	 the	 type	 of	 mapping	 sequence	 used.	 Several	
recent	 publications	 have	 reported	 “normal”	 T1	 ranges	 for	 healthy	 subjects;	 these	 ranges	 are	
discussed	later	in	the	article.	By	providing	a	reproducible	standard	of	T1	and	T2	values,	myocardial	
mapping	may	reduce	interpretation	variability	and	error	related	to	subjective	analysis	and	image	
artifact.	 Quantitative	 tissue	 characterization	 with	 mapping	 may	 also	 be	 better	 suited	 for	
longitudinal	assessment	of	patients	with	cardiac	disease	than	the	arbitrary	scale	used	at	traditional	
cardiac	MR	imaging.		
Myocardial	disease	affects	the	cellular	and	extracellular	composition	of	myocardial	tissue,	thereby	
altering	 the	 native	 T1	 and	 T2	 signals.	 In	 general,	 a	 prolonged	 native	 myocardial	 T1	 signal	 is	
encountered	in	various	disease	states	that	result	in	edema	or	fibrosis,	and	in	amyloid	deposition.	
Shortening	of	 the	native	T1	 relaxation	 time	can	be	seen	with	siderosis,	Anderson-Fabry	disease,	
and	fat	deposition,	although	these	diseases	are	less	commonly	encountered	in	routine	practice.		
Contrast-enhanced	T1	Mapping		
The	 use	 of	 gadolinium-based	 contrast	 agents	 shortens	 the	 native	 T1	 relaxation	 time	 of	 myo-
cardium	by	several	hundred	milliseconds.	Areas	with	a	disproportionate	accumulation	of	contrast	
material	 (fibrosis)	 will	 therefore	 exhibit	 shorter	 T1	 relaxation	 times	 than	 normal	 myocardium	
when	using	contrast-enhanced	T1	mapping	sequences	(Figure	6).	Whereas	nonenhanced	T1	map	
values	 are	 a	native	property	of	 the	myocardium,	 contrast-enhanced	T1	map	values	 are	 variable	
and	 highly	 dependent	 on	 (a)	 variable	 weight-based	 contrast	 agent	 dosing,	 (b)	 the	 exact	 time	
elapsed	after	contrast	agent	administration	before	images	are	acquired,	(c)	renal	clearance	of	the	
contrast	agent,	and	(d)	displacement	of	contrast	material	by	the	hematocrit.	Thus,	nonenhanced	
T1	mapping	is	less	variable	(within	the	same	patient	and	across	patients)	than	contrast-enhanced	
T1	 mapping	 because	 of	 the	 variability	 in	 the	 exact	 time	 of	 image	 acquisition	 with	 contrast-
enhanced	mapping.		
Figure	6.	Contrast-enhanced	T1	mapping:	a)	same	plane	acquired	with	different	T1;	b)	T1	map;	c)	Graph	of	a	
curve-fitting	analysis	for	a	single	pixel	(Courtesy	of	Hamlin	S	et	al;	Radiographics	2014)		
		
	
	
	
	
	
	
	
	
Tagging	
In	 1988	 it	 was	 introduced	 a	 new	 CMR	 technique	 to	magnetically	 label	 or	 tag	 different	 regions	
within	the	heart	wall.	The	basic	 idea	was	to	create	noninvasive	markers	within	the	heart	wall	by	
applying	saturation	planes	perpendicular	to	the	imaging	plane	at	the	electrocardiographic	trigger	
signal	 before	 image	 acquisition.	 During	 the	 subsequent	 image	 acquisition,	 reduced	 signal	 is	
obtained	from	the	saturated	tissue.	Therefore,	the	cut	line	of	the	image	plane	and	the	saturated	
plane	appears	as	a	hypointense	or	black	line	on	the	images	(Figure	7).	
Figure	7.	Tagging	image.	
	
A	 fast	 way	 to	 generate	 a	 tagging	 pattern	was	 introduced	 by	 Axel	 and	 Dougherty	 in	 1989.	 This	
method	is	known	as	spatial	modulation	of	magnetization	(SPAMM);	it	is	fast	and	it	can	be	applied	
twice,	in	2	orthogonal	directions,	yielding	a	grid	pattern.	With	SPAMM	either	sharper	stripes	or	a	
sinusoidal	intensity	variation	can	be	obtained.	
Because	the	magnetization	is	a	property	of	the	tissue,	the	tag	lines	move	along	with	the	tissue	in	
which	they	are	created.	When	created	at	end	diastole,	the	lines	will	deform	with	the	myocardium	
during	contraction,	and	become	undeformed	again	during	subsequent	relaxation.	From	this	it	can	
be	recognized	that	the	deformed	tag	pattern	reflects	the	underlying	motion	of	the	heart	wall.	By	
tracking	 the	 motion	 of	 the	 tag	 lines	 throughout	 the	 cardiac	 cycle,	 the	 intramural	 myocardial	
deformation	 can	be	quantified.	 The	 tags	 gradually	will	 fade	during	 the	 cardiac	 cycle	because	of	
tissue	T1	relaxation	and	the	imaging	radiofrequency	pulses.	This	fading	may	hamper	assessment	of	
regional	myocardial	function,	especially	the	analysis	of	the	relaxation	of	the	heart	during	diastole.	
	
Tagged	image	analysis	
The	analysis	method	used	to	extract	information	on	myocardial	function	from	the	tagged	images	
depends	on	the	clinical	purpose	for	which	it	is	applied.	
1)	Visual	assessment	requires	tags	that	can	be	easily	followed	by	eye,	and	therefore	the	tag	lines	
should	 be	 as	 sharp	 as	 possible.	 For	 this	 purpose	 image	 quality	 is	 essential,	 whereas	 temporal	
resolution	 and	 the	 applicability	 of	 semiautomatic	 postprocessing	 become	 less	 important.	 This	
means	 for	 the	 image	acquisition	that	a	 rectangular	 intensity	profile	of	 the	tag	 lines	 is	preferred,	
and	that	grid-tagged	images	are	presented	to	the	observer.		
2)	Quantitative	 assessment	 of	myocardial	 deformation	with	 (semi)automated	 analysis	methods,	
however,	other	types	of	tagging	images	may	be	more	suitable.	
Basically,	3	types	of	analysis	methods	can	be	discerned:	
• The	first	type	of	method	aims	at	the	detection	and	tracking	of	the	tag	lines	in	the	images	
(Software	programs	such	as	Findtags	and	SPAMMVU).	
• The	 second	 type	 is	 based	 on	 optical	 flow,	 a	 method	 originating	 from	 machine	 vision	
applications,	 which	 determines	 the	 motion	 of	 the	 object	 in	 the	 image	 by	 assessing	
temporal	and	spatial	changes	in	image	intensity.	
• The	third	type	is	the	harmonic	phase	(HARP)	analysis.	The	HARP	method	calculates	for	each	
pixel	the	spatial	phase	in	the	periodic	tagging	pattern.	This	phase	can	be	used	to	track	the	
points	through	the	cardiac	cycle,	or	to	calculate	the	deformation	directly,	by	calculating	the	
regional	 spatial	 frequency	of	 the	 tagging	pattern	and	 comparing	 it	with	 the	undeformed	
frequency.	Because	of	its	almost	fully	automated	nature,	HARP	is	currently	the	most	widely	
used	analysis	method.	
	
Strain	analysis	
Strain	 analysis	 describes	 the	 change	 of	 shape	 of	 material	 (i.e.,	 myocardium)	 resulting	 from	
deformation.	Strain	is	independent	of	rigid	body	motion	(translation	and/or	rotation)	and	does	not	
necessarily	need	an	external	reference	system.	
For	 interpretation	 of	 normal	 strains,	 a	 coordinate	 system	 is	 required.	 Two	 different	 coordinate	
systems,	 the	 radial/fiber/cross	 fiber	 system	 and	 the	 radial/circumferential/	 longitudinal	 system,	
are	used	for	this	purpose.	Using	this	coordinate	system,	myocardial	deformation	can	be	described	
in	a	more	intuitive	way:		
1)	 Radial	 strain,	 representing	 deformation	 of	 the	 heart	 in	 the	 radial	 direction	 (i.e.,	 toward	 the	
center	of	the	ventricle).	Positive	radial	strain	during	systole	reflects	the	 local	contribution	of	the	
myocardium	to	wall	thickening,	andnegative	radial	strain	during	systole	implies	local	wall	thinning	
(dyskinesia);	
2)	 Circumferential	 strain,	 reflecting	 intramural	 circumferential	 shortening.	 A	 negative	 value	 is	
related	to	myocyte	contraction,	and	a	positive	value	indicates	systolic	bulging;	
3)	Longitudinal	strain,	reflecting	the	regional	amount	of	myocardial	shortening	from	base	to	apex	
(negative	value).	
The	strain	 rate	can	be	derived	 from	the	different	strain	measures	by	dividing	strain	by	 the	 time	
information	(T)	from	each	time	frame:	
Strain	rate=	Strain	(t2)-Strain	(t1)/(t2-t1)	
Time	derivative	of	strain	is	the	strain	rate	(1/s)	and	is	of	importance	in	assessing	the	relaxation	of	
the	 ventricle.	Quantification	 of	 the	 strain	 rate	 allows	 detailed	 evaluation	 of	 left	 ventricular	 (LV)	
diastolic	function.	
In	addition	to	the	normal	strains,	3	shear	angles	can	be	calculated:	
• the	radial-circumferential	shear	angle,	
• the	radial-longitudinal	shear	angle,	
• the	circumferential-longitudinal	shear	angle.	
The	 circumferential-longitudinal	 shear	 angle	 describes	 the	 twisting	 motion	 of	 the	 heart	 and	 is	
closely	related	to	torsion	of	the	LV.	
Cardiovascular	 magnetic	 resonance	 tissue	 tagging	 also	 offers	 the	 opportunity	 to	 quantify	
myocardial	 torsion	(Figure	8).	Torsion	 is	defined	as	 the	circumferential-longitudinal	shear	on	the	
epicardial	 surface	 between	 2	 short-axis	 slices.	 In	 the	 LV,	 torsion	 and	 untwisting	 is	 the	 result	 of	
contraction	and	relaxation	of	the	spiraling	myofibers.	
Figure	 8.	 Ventricular	 torsion	 and	 untwisting.	 Torsion	 and	 untwisting	 are	 the	 result	 of	 contraction	 and	
relaxation	 of	 the	 spiraling	 subepicardial	 and	 subendocardial	myofibers.	 The	 net	 ventricular	 torsion	 is	 the	
result	of	the	subepicardial	contraction	and	subendocardial	counterbalancing	contraction.	
	
	
Feature	Tracking	
FT-CMR	has	been	explored	on	stacks	of	2D	cine	images,	with	a	typical	slice	distance	of	6	to	8	mm	
and	strong	contrast	between	blood	pool	and	myocardium,	but	with	a	lower	in-plane	spatial	(1	to	2	
mm)	and	temporal	resolution	(commonly	30	phases	per	heart	cycle)	than	with	2D-STE.	
FT-CMR	on	2D	stacks	suffers	also	from	through-plane	motion	effects.	Temporal	averaging	may	
result	in	lower	strain	values	for	FTCMR	in	comparison	to	STE.	Due	to	the	lack	of	intramyocardial	
features,	FT-CMR	algorithms	focus	on	the	endocardial	and	epicardial	borders	with	a	stronger	
weighing	of	endocardial	deformation	explaining	some	of	the	differences	in	results	found	in	direct	
comparisons	of	FT-CMR	and	STE	(Figure	9).	
Figure	9.	Tissue	Tracking	
	
From	the	displacement	estimations	provided	by	these	tracking	methodologies	a	series	of	
deformation	parameters	relevant	to	assess	the	mechanics	of	the	myocardium	(Table	4).	
Table	4.	Deformations	parameters	
	
Stress	single-photon	emission	computed	tomography	
Stress	single-photon	emission	computed	tomography	(SPECT)	is	a	validated	imaging	tool	providing	
information	 on	 the	 physiological	 significance	 of	 flow-limitation	 and	 sarcolemmal	 membrane	
integrity.	 It	 is	 also	 a	 cost-effective	 risk	 assessment	 tool	 for	major	 adverse	 cardiac	 events	 in	 the	
general	and	diabetic	populations.	Moreover,	LV	function	analysis	by	SPECT	enhances	its	prognostic	
and	diagnostic	ability,	particularly	in	the	prediction	of	cardiac	death.	Reliable	automatic	algorithms	
of	SPECT	provide	semiquantitative	assessment	of	myocardial	perfusion,	LVEF,	LV	volumes,	regional	
myocardial	wall	motion	and	thickening	and	diastology.	
A	simultaneous	assessment	of	myocardial	perfusion	and	LV	function	is	important	for	the	diagnosis	
of	cardiomyopathy,	particularly	dilated	cardiomyopathy,	and	could	also	be	useful	 in	DCM.	SPECT	
can	 accurately	 assess	 both	 myocardial	 perfusion	 and	 ventricular	 function	 in	 diabetic	 patients,	
providing	 important	 information	 for	 their	 management.	 It	 also	 has	 high	 sensitivity	 in	
differentiating	 ischemic	 from	 non-ischemic	 cardiomyopathy.	 Nevertheless,	 factors	 other	 than	
coronary	 narrowing	 could	 play	 a	 role	 in	 the	 pathogenesis	 of	myocardial	 dysfunction	 in	 diabetic	
patients,	 including	 endothelial	 dysfunction,	 interstitial	 edema	 and	 fibrosis,	 coronary	 collateral	
circulation,	 impaired	modulation	of	vascular	growth	and	remodeling.	As	a	result,	SPECT	could	be	
helpful	in	these	situations.	
Positron	emission	tomography	
Among	 the	 available	 imaging	 modalities,	 only	 positron	 emission	 tomography	 (PET)	 allows	
quantitative	 assessment	 of	 myocardial	 blood	 flow	 using	 radiotracer	 kinetics.	 However,	 the	
combined	 images	 by	 MRI	 and	 PET	 provide	 a	 high	 spatial	 resolution	 detection	 of	 myocardial	
metabolic	abnormalities	and	currently	represent	the	most	valuable	imaging	analysis	for	diagnosis	
and	prognosis	 in	DM.	This	 recent	 sophisticated	 imaging	modality	 is	also	 indicated	particularly	 in	
the	case	of	diabetic	patients	with	or	at	risk	of	CAD,	since	CT	is	currently	considered	very	reliable	in	
evaluating	coronary	artery	calcium	plaque	burden	and,	with	the	aid	of	contrast	agents,	it	provides	
an	accurate	evaluator	of	the	coronary	arterial	system.	
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EXPERIMENTAL	CONTENT	
	
Diffuse	myocardial	fibrosis	in	patient	with	diabetes	mellitus	type-II	(DM-II)	assessed	by	Cardiac	
Magnetic	Resonance	T1	mapping	technique		
ABSTRACT	
Purpose:	Diabetic	cardiomyopathy	(DCM)	can	be	cause	of	a	progressive	dysfunction	of	ventricular	
contractility	 with	 the	 evolution	 to	 heart	 failure,	 independently	 of	 ischaemic	 heart	 disease	 or	
hypertension.	 Early	 stages	 of	 DCM	 are	 asymptomatic	 and	 characterized	 by	 various	 degrees	 of	
myocardial	 fibrosis.	 Our	 aim	 is	 to	 non-invasively	 detect	 myocardial	 fibrotic	 infiltration	 in	 DM-II	
patients,	 to	 assess	 its	 relationship	with	 ventricular	 function	 abnormalities	 and	 to	 compared	our	
results	with	a	group	of	healthy	controls.	
Methods	 and	 Materials:	 100	 patients	 affected	 by	 DM-II	 (57	 man,	 43	 women)	 with	 preserved	
ventricular	 function	 and	 no	 history	 of	 ischaemic	 disease	 and	 20	 matching	 controls	 underwent	
contrast	 cardiac	MR	 (CMR)	between	September	2014	and	 July	2017.	 Imaging	protocol	 included:	
modified	 Look-Locker	 sequence	 before	 and	 20	 minutes	 after	 a	 double	 dose	 of	 0.1	 mmol/kg	
gadoterate	 meglumine	 injection;	 T2-mapping;	 ventricular	 function	 module;	 tagged-cineMR	
module	and	 late	gadolinium	enhanced	(LGE)	 imaging.	Native	myocardial	T1	 (nT1)	and	T2	values,	
extracellular	 volume	 fraction	 (ECV),	 ventricular	 torsion	 angle	 and	myocardial	 strain	 values	 have	
been	calculated	and	correlated	to	glycated	haemoglobin	(HbA1c)	and	duration	of	disease.	Pearson	
Correlation,	Mann-Whitney	test	and	unpaired	T-test	were	used	for	statistical	analysis.	
Results:	Patient	group	had	higher	nT1	and	ECV	values	compared	to	controls	(1018.29±73.28	ms	vs.	
975±38	 ms,	 29.2±0.07%	 vs.	 22.8±4.3%	 respectively,	 p<0.05	 for	 both),	 whereas	 no	 significant	
differences	occurred	in	T2	measurements	(47.61±2.7ms	vs.	47.0±2.8ms	respectively,	p=0.23).	nT1	
and	 ECV	 correlated	 with	 HbA1c	 (nT1:	 r2=0.99,	 p<0.0001;	 ECV:	 r2=0,07;	 p<0.005)	 and	 disease	
duration	 (nT1:	 r2=0.99,	p<0.0001;ECV:	 r2=0,70	p<0,001)	 in	DM-II	patients.	nT1	and	ECV	correlate	
positively	torsion	(nT1:	r2=0.31,	p<0.001;	ECV:	r2=0.30;p<0.001)	and	negatively	with	strain	values	
in	 tagged-cineMR	analysis	 (nT1	with	global	 longitudinal	and	circunferential	 strain:	both	 r2=-0.97,	
p<0.0001;	 ECV:	 r2=0.63	 and	 r2=0.76,	 p<0.0001).	 LGE	 with	 ischemic	 pattern	 was	 found	 in	 eight	
patients	as	marker	of	silent	infarction.	
Conclusion:	 In	 DM-II	 patients	 with	 preserved	 ventricular	 function,	 HbA1c	 values	 and	 disease	
duration	 showed	 a	 significant	 correlation	 to	myocardial	 nT1	 and	 ECV	 increase,	 as	 reflection	 of	
diffuse	fibrosis,	and	geometrical	modification.	
INTRODUCTION	
Diabetic	 cardiomyopathy	 (DCM)	 is	 defined	 by	 the	 presence	 of	 structural	 and	 functional	
abnormalities	 of	 the	 myocardium	 in	 diabetic	 patients	 without	 coronary	 artery	 disease,		
hypertension,	congenital	or	valvular	heart	diseas	[1,2].	
The	 development	 of	 myocardial	 dysfunction	 in	 diabetes	 has	 been	 attributed	 to	 the	 effects	 of	
hyperglicemia:	the	high	levels	of	advanced	glycation	end	products	(AGEs)	deposition	and	oxidation	
of	proteins	and	lipids	are	considered	as	the	major	pathoges	of	high	glucose-induced	cellular	injury	
[3].	These	elements	in	association	with	microvascular	rarefaction	and	autoimmunity	contribute	to	
produce	myocardial	 fibrosis	and/or	myocardial	hypertrophy:	 chronic	myocardial	 injury	 results	 in	
ventricular	 remodelling	 and	 progressive	 impairment	 of	 myocardial	 contraction	 (evolving	 from	
diastolic	to	combined	diastolic-systolic	dysfunction	[4,5].	
Early	recognition	of	DCM	in	pre-clinical	stage	is	currently	challenging	because	patients	are	usually	
asymptomatic	 and	 ventricular	 function	 and	morphology	 remains	 normal	 for	 ages	 appearing	 not	
easily	detectable	by	the	conventional	cardiovascular	imaging	exams	(echo,	CMR	and	scintigraphy)	
[6].	In	particular	subendocarial	dysfunction	is	the	first	sign	of	structural	changes	in	DCM	and	it	can	
be	 evaluated	 using	 conventional	 Doppler	 Echocardiography,	 tissue	 doppler	 imaging	 (TDI)	 and	
speckle	 tracking	 echocardiography	 (STE)	 techniques	 [7,8].	 These	 methods	 suffers	 of	 some	
limitations	such	as	high	inter	and	intraobserver	variability,	angle	dependence,	noise	interference,	
non	discrimination	between	active	and	passive	motion,	irregular	ventricular	remodelling	and	wall	
thinning	[8].	
Cardiac	 Magnetic	 Resonance	 Imaging	 (CMR)	 compare	 to	 TEE	 provides	 extra-information	 about	
myocardial	fibrosis	and	subclinical	ischemia,	as	premature	parameters	of	cardiac	dysfunction.	CME	
with	 the	 “late	 gadolinium	 enhancement”	 (LGE)	 technique	 after	 injection	 of	 contrast	medium	 is	
considered	the	reference	diagnostic	tool	for	the	non-invasively	detection	“in	vivo”	of	macroscopic	
myocardial	fibrosis	in	a	large	spectrum	of	ischemic	and	non-ischemic	cardiac	diseases	[9-11].	This	
technique	is	very	effective	in	the	localization	and	definition	of	focal	fibrosis	but	it	does	not	work	
equally	in	the	detection	of	diffuse	fibrosis	and	it	is	burden	by	the	operator	dependence	[9].	
Diffuse	 myocardial	 fibrosis	 can	 be	 indirectly	 assessed	 through	 geometrical	 modifications	 of	
myocardial	contraction	in	DCM	assessed	by	the	technique	of	tagging	MR	[12].	
Moreovere	 the	 new	 technique	 of	 T1	 mapping	 has	 been	 proposed	 as	 an	 objective	 method	 to	
directly	measure	the	signal	intensity	of	myocardium	before	the	administration	of	contrast	and	to	
measure	 myocardial	 extracellular	 matrix	 (ECM):	 this	 can	 be	 quantify	 in	 terms	 of	 extracellular	
volume	 fraction	 (ECV)	 after	 the	administration	of	 contrast	 [13].	 It	 provides	histologically-proven	
evidence	of	diffuse	 fibrosis	 in	a	broad	spectrum	of	cardiomyopathies,	 is	highly	 reproducible	and	
sensitive	[14-17].	In	particular	it	has	been	showed	a	significantly	shorter	global	contrast-enhanced	
myocardial	T1	 time	 in	diabetic	patients	compared	with	healthy	controls	and	 its	association	with	
more	impaired	longitudinal	myocardial	systolic	and	diastolic	function	[18,	19].	
In	 DCM	 the	 relationship	 between	 T1	 mapping	 parameters,	 functional	 and	 clinical	 parameters	
(HbA1c	and	duration	of	disease)	should	be	investigate.	
The	primary	aim	of	our	study	is	to	objectively	detect	and	quantify	the	diffuse	fibrotic	infiltration	of	
myocardium	 in	a	population	of	patients	with	diabetes	mellitus	 type	 II	 (DM-II)	using	T1	mapping	
technique	 and	 to	 compare	 these	 results	 to	 healthy	 controls.	 This	 study	 will	 also	 examine	 the	
correlations	between	global	 T1	 values	 (native	T1	and	ECV)	with	myocardial	 function	 (in	 term	of	
strain	 and	 torsion)	 and	 to	 correlate	 these	 results	with	duration	of	diabetes	 and	HbA1c	 levels	 in	
order	to	identify	new	MR	markers	of	DCM	in	the	asymptomatic	phase	of	the	disease	and	to	predict	
disease	progression.	
	
MATERIAL	AND	METHODS	
1.1 Patients	enrollment		
100	 patients	 affected	 by	 DM-II	 and	 20	 healthy	 controls	 were	 prospectively	 enrolled	 by	 the	
Department	 of	 Clinical	 and	 Molecular	 Endocrinology	 between	 April	 2014	 and	 July	 2017	 and	
classified	in	gender-based	age-matched	groups.	
Inclusion	criteria	were:	age	35-75	yrs;	HbA1c	<	10%;	normal	blood	pressure	(BP)	or	hypertension	
under	 pharmacological	 control	 by	 at	 least	 5	 years;	 BMI	 <	 40;	 diagnosis	 of	 diabetes	mellitus	 >	 3	
years.	
MR	Exclusion	criteria:		standard	contraindication	to	Magnetic	Resonance;	age	<	18	years;	severe	
arrhythmia	 or	 tachycardia;	 history	 of	 significant	 coronary	 artery	 disease,	 previous	 myocardial	
infarction	or	 cardiac	 inflammatory	disease;	 history	or	 evidence	 systemic	 autoimmune	disorders,	
sarcoidosis,	 amyloidosis	 or	 congenital	 heart	 disease;	 history	 or	 evidence	 of	 uncontrolled	
hypertension;	chronic	Kidney	disease	Stage	4	and	5	(GFR	<	30	mL/min/1.73m2)		
All	 patients	 underwent	 blood	 test,	 physical	 examination	 and	 measure	 of	 anthopometric	
parameters	prior	the	MR	examination.	Moreover	all	patients	underwent	ad	ECG	and	Transthoracic	
Echocardiography	(TTE)	in	order	to	satisfy	inclusion	criteria.	TTE	inclusion	criteria	are	summarized	
in	Table	1.	
Table	1.	TTE	inclusion	criteria	
Diastolic	function	 I	grade	
Systolic	function	 FE	>45<55%	
Regional	contraction	 Absence	of	akinesia	or	dyskinesia	
Thickness	of	SIV	 >11	mm	in	man	and	>10	mm	in	women	
Valvular	stenosis/insufficiency	 mild	
Aneurism	 no	
	
Non-diabetic	subjects	with	normal	LV	function	and	normal	value	of	glycosylated	haemoglobin	(<	
3.5	%)	were	enrolled	 as	 a	 control	 group;	 there	were	 included	patients	previously	 scheduled	 for	
CMR	with	other	 indications,	 such	as	arrhythmogenic	 right	ventricular	dysplasia,	non-compaction	
cardiomyopathy	or	atrial	fibrillation	and	with	CMR	negative	results.	
All	 subjects	 that	 during	 the	 CMR	 exam	 showed	 evidence	 of	 macroscopic	 late	 enhancement	
myocardial	areas	indicative	for	fibrosis/scar	from	previous	myocardial	infarction	were	excluded.	
Consent	 of	 the	 local	 ethical	 comity	was	 obtained	 and	 all	 informed	 consents	 of	 patients	 on	 the	
study	were	collected.	
1.2 Cardiovascular	Magnetic	Resonance	
All	patients	underwent	a	contrast	cardiac	MR	study	(CMR)	in	our	Department	using	a	1.5	T	scanner	
(Siemens	Avanto,	Erlangen,	Germany).	
All	patients	and	healthy	controls	underwent	a	CMR	exam	using	the	following	protocol:	
- Breath-hold	ECG-gated	balanced-steady	state	 free	precession	 (bSSFP)	cine-MR	sequences	
in	 standard	 fashion,	 according	 to	 the	 true	 anatomic	 axes	 of	 the	 heart,	 to	 assess	 bi-
ventricular	morphology	and	function;	
- Tagging	cine-MR	sequences,	acquired	in	short	axis,	to	assess	strain	and	torsion;	
- T2	STIR	sequences	were	acquired	on	a	basal,	mid	and	apical	plane	in	order	to	rule	out	the	
presence	of	myocardial	edema;	
- T2	mapping	sequences	were	acquired	on	the	same	basal,	mid	and	apical	plane	to	validate	
the	absence	of		myocardial	edema;	
- First	 pass	 imaging	 were	 acquired	 during	 the	 injection	 of	 0.1	 mmol/kg	 of	 Gadoterate	
meglumine.	
- Early	 gadolinium	enhanced	 images	were	 acquired	 by	 performing	 T1-weighted	 turbo	 spin	
echo	 sequence	 in	 four	 identical	 axial	 slices	 both	 before	 and	 three	 minutes	 after	
intravenous	administration	of	the	first	bolus	of	contrast	medium	in	order	to	evaluate	early	
myocardial	enhancement.	
- Novel	 Modified	 Look-Locker	 Inversion	 recovery	 sequences	 (MOLLI)	 were	 acquired	 on	 a	
mid-ventricular	short	axis	view	before	contrast	administration	and	after	a	double	injection	
of	0.1	mmol/Kg	of	gadolinium	(the	second	injection	was	done	3	minutes	after	the	first	one)	
at	3,	5,	10,	15	and	20	minutes	in	order	to	estimate	the	Extracellular	volume	fraction	(ECV).		
- Traditional	 contrast-enhanced	 T1-weighted	 inversion	 recovery	 images	 were	 acquired	
between	15	and	20	minutes	after	CM	 injection	on	 short-axis	 view	using	 the	 same	 image	
geometry	as	for	the	MOLLI	sequences	for	late	gadolinium	enhancement	imaging	(LGE).	
Parameters	of	all	sequences	are	summarized	in	Table	2.	
Table	2.	MR	sequences	parameters	
	
	
	1.3	Imaging	evaluation	
All	 images	were	 evaluated	by	 two	double-blinded	observers	 using	 a	 cardiac	 dedicated	 software	
(CMR	42,	Circle	Cardiovascular	Imaging,	Canada).	
1.3.1	Ventricular	function	analysis	
For	the	ventricular	volumes	analysis,	the	epi-	and	endocardial	contours	of	the	left	ventricle	were		
drawn	on	b-SSFP	cineMR	images	at	end-diastole	and	end-systole	in	order	to	measure	end-diastolic	
volume	(EDV),	end-systolic	volume	(ESV),	stroke	volume	(SV),	ejection	fraction	(EF)	and	myocardial	
mass	(MASS);	all	values	were	indexed	for	antropometric	data	(body	mass	index).	
1.3.2	Tagging	analysis	
HARP	software	tool	was	used	on	these	 images	 for	evaluating	myocardial	 strain	and	torsion.	The	
epi-	 and	 endocardial	 contours	 of	 the	 left	 ventricle	 were	 drawn	 on	 tagging-cineMR	 images	 in	 a	
single	phase	for	each	sequences.	The	software	automatically	generated	24	points	for	each	contour	
drawn	and	it	is	extended	for	each	place	on	short	axis	view.	
Torsion	angle	between	basal	and	apical	planes	was	calculated	as	an	average	of	 rotation	of	each	
points.	Global	torsion	of	left	ventricle	(θ°)	has	been	calculated	as	the	difference	between	positive	
rotation	of	the	apex	and	negative	rotation	of	the	basis:	θ=	θ	apice	–	θ	base.	The	greater	systolic	
torsion	was	measured	as	the	greated	value	of	θ	during	all	cardiac	cycle.	
1.3.3.	T2	STIR	analysis	
The	epi-	and	endocardial	contours	of	the	basal,	middle	and	apical	planes	acquired	on	left	ventricle	
were	 	drawn	on	T2-STIR	 images	and	a	 reference	ROI	was	put	on	skeletal	muscle	 (i.e.	perctoralis	
muscle)	and	T2	ratio	was	calculated	as	previously	published	[20].	
1.3.4.	T2	mapping	analysis	
On	T2	map	a	ROI	was	drawn	on	 interventricular	 septum	on	 the	basal,	middle	and	apical	planes	
acquired	on	left	ventricle.	
	
1.3.5.	T1	mapping	analysis	
For	the	T1	mapping	analisis	the	epi-	and	endocardial	contours	of	the	left	ventricle	were	drawn	on	
basal,	middle	 and	 apical	 planes	 using	 as	 a	 reference	 the	 blood	 into	 left	 ventricle	 on	 both	 pre-
contrast	(native	T1	of	myocardium,	nT1)	and	post-contrast	images	(Extracellular	Volume	Fraction,	
ECV)	according	to	the	note	formule	[21]	(Figure	1).		
Figure	1:	T1	mapping:	a)	Pre-contrast	measurement;	b)	post-contrast	
	
1.3.6.	LGE	analysis	
LGE	images	were	qualitatively	assessed	in	order	to	detect	the	presence	of	macroscopic	myocardial	
areas	 of	 enhancement	with	 coronary	 distribution	 and	 subendocardial	 involvement	 suggesting	 a	
previous	myocardial	 infarction,	as	 this	 is	an	esclusion	criteria.	However,	patients	with	 little	 focal	
areas	 of	 enhancement	 in	 other	 locations	 were	 included	 as	 these	 abnormalities	 may	 represent	
small	fibrotic	areas	as	result	from	hyperglycemia	or	due	to	small	ischemic	injury.	
	1.4	Correlation	between	cardiac	function,	T1	mapping	and	ECV	with	clinical	data.	
All	data	collected	on	cardiac	function	(strain,	torsion),	T1	mapping	and	ECV	values	were	compared	
to	HbA1c	levels	and	duration	of	disease.	In	order	to	assess	if	there	are	any	difference	between	DM	
patients	 without	 hypertension	 and	 DM	 patients	 with	 hypertension	 all	 study	 population	 was	
divided	in	two	subgroups	and	T1	mapping	values	were	separately	compared	to	HbA1c	levels	and	
duration	 of	 disease.	 Moreover	 all	 data	 collected	 were	 compared	 between	 DM	 II	 patients	 and	
controls.	
1.5	Statistical	analysis	
Statistical	 analysis	 was	 done	 using	 SPSS	 Software	 for	 Windows,version	 20.0	 (SPSS,Inc,Cary,NC	
package).	 All	 continuous	 variable	were	 expressed	 as	 average±SD.	 All	 correlations	were	 done	 by	
calculating	 the	 Pearson's	 correlation	 coefficients	 and	 differences	 between	 DM	 II	 patients	 and	
controls	were	done	using	the	unpaired	t	test	for	normal	distribution	of	data	or		the	Mann-Whitney	
test	for	non-normal	distribution.	There	were	considered	statistical	significant	only	P	value<0,005.	
	
RESULTS	
1.1 Study	population		
100	 patients	 affected	 by	 DM-II	 (57	 man,	 43	 women;	 mean	 age	 64,7+7,3	 yo)	 and	 20	 healthy	
controls	underwent	contrast	cardiac	MR	between	September	2014	and	July	2017.	All	features	of	
DM-II	patients	were	summarized	in	Table	3	and	4.	
	
	
	
	
	
	
Table	3.		Features	of	study	population	
Features	 Women	
N	=43	
Man	
N	=	57	
P		
Age	 66.8	±	5.1	 64.2	±	8.3	 0.60	
BMI	 28.9	±	4.1	 28.4	±	3.7	 0.63	
Waist	
Circumference	cm		
99.8	±	8.5	 103.1	±	9.7	 0.29	
Glycemia		mg/dL		 133.7	±	43.1	 145.6	±	45.2	 0.21	
HbA1c		%		 6.7	±	1.0	 6.9	±	0.9		 0.32	
Trunk	fat	*		%		 34.5	±	3.6	 24.1	±	4.5	 0.00	
CrCl		mL/min		 94.5	±	26.6	 114.6	±	36.5	 0.19	
ASP		mmHg		 129.4	±	16.3	 124.7	±	13.1	 0.48	
ADP		mmHg		 71.6	±	9.1	 73.8	±	8.9	 0.32	
HR		batt/min		 74.5	±	12.6	 67.9	±	7.6	 0.08	
Age	of	disease	DM2	 11.9±	8	 13.2	±	8.1	 0.90	
BMI,	 Body	Mass	 Index;	 CrCL,	 Creatinine	 Clearance;	 ASP,	 arterial	 systolic	 pressure;	 ADP,	 artedial	
dyastolic	pressure;	HR,	Heart	rate	
	
	
	
	
	
	
Table	4.	Comorbidities	of	study	population	
Comorbidy	 Women	
(43)	
Man	
(57)	
p	
Hypertension		 26	(61.9)		 32	(61.5)		 0.97	
Carotid	atherosclerosis	 5	(11.9)		 16	(30.8)		 0.45	
Dislipidemia	 30	(71.4)		 34	(61.5)		 0.66	
Hypogonadis	age-related		 42	(100)		 8	(15.4)		 0.00	
Complications	 Women	
%		
Man	
%		
p	
Diabetic	Nephropathy		 5	(11.9)		 12	(23.1)		 0.49	
Diabetic	Neuropathy		 5	(11.9)	 10	(19.2)		 0.3	
Diabetic	Retinopathy		 4	(9.5)		 2	(3.8)	 0.4	
11	(11%)	patients	were	excluded	from	the	analysis:	8	(8%)	because	of	the	evidence	of	macroscopic	
late	 enhancement	myocardial	 areas	 indicative	 previous	myocardial	 infarction;	 1	 (1%)because	 of	
the	evidence	of	lung	mass	(resulted	at	biopsy	as	a	lung	cancer)	and	2	(2%)	patients	decided	to	stop	
the	MR	examination	because	of	fatigue.	
1.2 Imaging	evaluation	
Functional	results,	including	tagging-MR	results,	were	showed	in	Table	5.	
	
	
	
	
	
	
Table	5.	Functional	results	of	left	ventricle	
Left	ventricle	Function	
	 DM	II	(n=57)	 Controls	(n=43)	 p	
LV-EDVi	(mL/m2)	 55.02±13.8	 55±9.2	 n.s.	
LV-ESVi	(mL/m2)	 21.6±8.3	 18±8.3	 n.s.	
LV-SVi	(mL/m2)	 69.2±8.3	 51±10.8	 n.s.	
LV-EF	(%)	 62.6±7.5	 68±6.9	 n.s.	
LV-Mass(g/m2)	 80.7±10.7	 66±10.9		 <	0.05	
Global	Radial	Strain	(%)	 51.5±11.5	 		43.2±9.3	 <	0.01	
TD	(mm)	 46.6±5	 43.2±25	 0.003	
IVS	(mm)	 11.2±2.2	 10.2±2	 0.001	
Time-to-peak	Radial	Strain	(ms)	 299.2±38.2	 	322.5±48.7	 <	0.05	
Global	Circumferential	Strain(%)	 -22.5±5.3	 	-20.5±3.6	 <	0.01	
Time-to-peak	Circum	Strain	(ms)	 3013±41.8	 	322.6±48.7	 <	0.05	
Global	Longitudinal	Strain	(%)	 -18.4±4.4	 -	24.4±4.3	 <	0.01	
Time-to-peak	Long	Strain	(ms)	 321.6±50.6	 310.8±49.8	 <	0.05	
Torsion	(°)	 13.7±3.4	 14.4	±	1.1	 <	0.05	
	
T2	ratio	and	T2	mapping	
Nobody	of	DM	II	patients	showed	myocardial	edema	on	T2	images	or	early	Gd	enhancement	after	
intravenous	administration	of	the	first	bolus	of	contrast	agent.	
T2	mapping	images	showed	no	significant	difference	between	DMII	patients	and	controls	(average	
of	47.6±2.7	ms	in	DM	II	vs	47±2.8	in	control	group.		
T1	mapping	
nT1	 mapping	 images	 showed	 values	 of	 1018,29±73,28	 ms	 in	 DM-II	 vs	 975±38	 ms	 controls	
(p<0.005)	(Graph	1).	Post-contrast	T1	values	at	15’	were	of	408,94±51,89	ms.	
ECV	values	 in	DM-II	patients	were	of	0,29±0,007	compare	to	controls	 in	which	were	of	0,22±3,2	
(Graph	1).	
Graph	1.	(a)	Correlation	of	nT1	values	between	DM-II	patients	and	Controls	and	(b)	Correlation	of	
ECV	values	between	DM-II	patients	and	Controls	
	
Late	Gadolinium	Enhancement	
LGE	images	showed	macroscopic	area	of	fibrosis	due	to	myocardial	infarction	in	8	patients	while	in	
7	there	were	shaded	area	of	aspecific	fibrosis	(Figure	2).	
Figure	2.	Silent	myocardial	infarction	discovered	during	MR	examination	in	67	yo	man	affected	by	
DM-II.	Late	Gadolinium	Enhancement	 images	showed	un	anterior	myocardial	 infarction	extended	
on	a)	basal,	b)	middle	and	c)	apical	planes.	
	1.3 Correlation	between	cardiac	function,	T1	mapping	and	ECV	with	clinical	data.	
There	 was	 an	 inverse	 correlation	 between	 T2	 map	 values	 in	 DM	 II	 patiens	 and	 HbA1c	 values	
(7.5±0.9;	r=-0.46;	p<0.0001),	while	no	correlation	was	observed	with	duration	of	disease.		
nT1	 values	 showed	 a	significant	 correlation	 with	 HbA1c	 levels	 (r2=0,99	 p<0,0001)	 and	 with	
duration	of	disease	(r2=0,99	p<0,0001).	
ECV	at	15’	showed	a	significant	correlation	with	HbA1c	levels	(r2=0,07	p<0,005)	and	with	duration	
of	disease	(r2=0,70	p<0,001).	
Correlations	between	left	ventricle	function	and	nT1	and	ECV	were	displayed	in	Table	6	and	Graph	
2.	
Table	6.	Correlation	between	left	ventricle	function	and	nT1	and	ECV	
	
	
Graph	 2.	 Correlation	 between	 nT1	 (a)	 and	 ECV	 (b)	 vs	 Radial,	 Circumferential	 and	 Longitudinal	
Strain	
	
No	 significant	 differences	 were	 found	 between	 nT1	 and	 ECV	 in	 DM-II	 patients	 without	
hypertension	and	DM-II	patients	with	hypertension	(p=0.70;	p=0,67).	
	
DISCUSSION	
DCM	 as	 a	 clinical	 entity	 remains	 unclear	 despinte	 many	 investigations	 have	 been	 done.	 It	 is	
defined	as	myocardial	dysfunction	that	occurs	independently	of	coronary	artery	disease,	valvular	
pathology	or	hypertension.	 It	has	been	associated	with	modifications	of	 left	ventricle	geometry,	
altered	function	and	tissue	abnormalities	[1,	4].	
In	 our	 study	 we	 found	 significant	 differences	 between	 nT1	 and	 ECV	 in	 DM-II	 patients	 versus	
controls.	 In	 particular	 the	 difference	 in	 ECV	 between	 DM-II	 patients	 and	 controls	 confirmes	
previous	 studies	 [22]	 suggesting	 that	 extracellular	 matrix	 expansion	 could	 be	 considered	 an	
important	 intermediate	 phenotype	 in	 diabetic	 patients	 detectable	 by	 ECV	 and	 treatable.	 The	
increase	 of	 ECV	 in	 DM-II	 is	 due	 to	 proliferation	 of	 myofibroblast	 activated	 by	 glucose	 and	
myocardial	 fibrosis	 [6].	 Moreover	 ECV	 in	 diabetic	 people	 is	 associated	 with	 subclinical	 cardiac	
dysfunction	[23],	it	is	associated	with	higher	rate	of	adverse	outcomes	in	the	setting	of	diabetes.	In	
literature	results	on	ECV	and	DCM	are	controversial	[24]:	DM-II	is	expected	to	be	associated	with	
high	value	of	ECV,	but	 some	studies	 showed	 similar	 results	between	DM-II	patients	and	control	
[25,	26].	 In	 these	studies	patient	population	consisted	of	young	adults	or	selection	criteria	were	
too	much	limited.	
nT1	 and	 ECV	 showed	 a	 significant	 correlation	 with	 HbA1c	 and	 in	 particular	 with	 duration	 of	
disease.	 Fibrotic	 changes	 in	myocardium	 are	 associated	with	 duration	 of	 disease	 in	 animal	 and	
human	 studies	 and	 ECV	 may	 be	 more	 sensitive	 than	 native	 and	 postcontrast	 T1	 in	 the	
confirmation	of	 these	structural	changes	 [27,	28].	The	relationship	between	diabetic	history	and	
ECV	indicates	that	ECV	may	represent	the	long-term	effects	of	DCM	on	the	myocardium.	
In	our	study	the	correlation	with	HbA1c	suggested	a	possible	role	of	HbA1c	as	a	marker	of	time-
averaged	 glucose	 level.	 Hyperglycemia	 can	 cause	 persistent	 (a	 few	 days)	 damage	 to	 cells	 by	
disrupting	 the	 signal	 feedback	 loop	 [xx]	 and	 hyperglycemia	 can	 promote	 the	 proliferation	 of	
cardiac	 fibroblast	 [29,	30].	This	 result	 is	 in	conflict	with	previous	studies	 in	which	no	correlation	
was	found	between	fibrosis	and	HbA1c	and	for	this	reason	we	think	that	it	should	be	investigate	in	
future	studies	on	bigger	population	of	diabetic	patients		[31].	
No	 significant	 differences	 were	 found	 between	 nT1	 and	 ECV	 in	 DM-II	 patients	 without	
hypertension	and	DM-II	patients	with	hypertension	 (p=0.70;	p=0,67)	and	 this	 result	 support	 the	
idea	that	farmacological	control	of	hypertension	enables	to	stop	or	slow	down	the	progression	of	
DCM.	On	 the	other	hand	uncontrolled	hypertension	 is	associated	with	progression	of	DCM	as	 it	
has	been	investigated	in	previous	studies	[32].	
Our	 results	 showed	 a	 significant	 relationship	 between	 impaired	 left	 ventricle	 contractility	
measured	by	tagging	and	the	increased	ECV	despite	the	EF	conserved	in	DM-II	patients.	These	data	
confirmed	 a	 previous	 study	 done	 by	 our	 group	 on	 DM-II	 patients	 [12]	 in	 which	 we	 found	 an	
uncoupling	between	longitudinal	and	circunferential	strain	and	a	resultant	modification	of	torsion	
angle	 of	 left	 ventricle	 as	 indirect	 signs	 of	 elevated	 myocardial	 collagen	 content.	 This	 this	
correlation	adds	value	to	T1	mapping	technique.	In	future	it	should	be	considered	the	new	feature	
tracking	technique	for	strain	and	torsion	measurements:	by	this	technique	is	it	possible	to	obtain	
measurement	of	myocardial	contractility	directly	on	cine	sequences	(bSSFP)	adquired	in	short	axis,	
4-chamber	and	long	axis	view	and	in	this	way	it	will	be	possible	reduce	MR	scan	time.	
LGE	 observed	 in	 8	 DM-II	 patients	 confirmed	 the	 capability	 of	 CMR	 to	 see	macroscopic	 area	 of	
fibrosis	 due	 to	 silent	myocardial	 ischemia	 (SMI)	 or	myocardial	 infarction	 (MI).	 This	 entity	 is	 an	
important	clinical	entity,	it	is	common	in	patients	with	diabetes	and	it	is	an	independent	predictor	
of	mortality	 [33].	 Its	 recognition	may	 lead	 to	early	 intervention	and	 changes	prognosis	of	 these	
patients.	In	a	substudy	of	the	Diabetes	Control	and	Complications	Trial	it	has	been	demonstrated	a	
4.3%	prevalence	of	LGE	consistent	with	unrecognized	MI	in	patients	with	type	1	diabetes	without	
clinical	 evidence	 of	 cardiovascular	 disease	 [34].	 Moreover	 recognition	 of	 MI	 is	 associated	 with	
poor	glycemic	control,	diabetic	nephropathy,	elevated	circulating	levels	of	HbA1c	and	albuminuria	
both	in	DM-II	and	DM-I	[35].	In	our	study	all	patient	with	MR	signs	of	MI	had	glycemic	control	but	
they	showed	a	trend	of	higher	levels	of	HbA1c.	
Nobody	 of	 DM	 II	 patients	 showed	 myocardial	 edema	 on	 T2	 images	 and	 T2	 mapping	 values	
confirmed	 the	 absence	 of	 edematous	 changes	 in	 myocardium.	 We	 used	 T2	 mapping	 to	 verify	
results	of	 the	 standard	measurements	done	with	T2-STIR	 images	 [36].	Moreover	 there	were	no	
significant	difference	between	DM	II	patients	and	controls.	
Our	 study	 has	 some	 limitations:	 first	 of	 all	 we	 need	 to	 collect	 data	 on	 a	 bigger	 population	 of	
diabetic	patients;	second	we	did	not	recruit	patients	with	a	GFR	≤	30	mL/min/1.7m2	,	and	it	should	
be	 interesting	 to	assess	nT1	values	also	 in	DM-II	patients	with	 impaired	 renal	 function	and	who	
cannot	undergo	CMR	with	contrast:	the	measurement	of	nT1	could	be	proposed	as	an	important	
marker	of	DCM	 in	 these	patients.	Third	we	did	not	exclude	coronary	artery	disease	by	coronary	
angiography	in	all	DM-II	patients	and	this	elements	may	have	introduced	a	bias.	Fourth	we	did	not	
correlate	our	 results	with	 circulating	biomarkers.	Moreover	 further	 research	 should	be	done	on	
gender	differences	in	DM-II	patients	in	functional	parameters,	nT1	and	ECV	and	to	correlate	these	
with	clinical	and	laboratory	markers.	
	
CONCLUSION	
DM-II	patients	showed	higher	nT1	and	ECV	values	compared	to	controls	using	the	technique	of	T1	
mapping.	 This	 method	 could	 be	 useful	 in	 the	 detection	 of	 interstitial	 fibrosis	 and	 in	 the	 early	
diagnosis	of	DCM.	 In	particular	 it	could	add	value	to	the	technique	of	MR-tagging	because	of	 its	
correlation	with	 contractile	 function.	 	Moreover	 T1	mapping	 values	 correlated	with	 duration	 of	
disease	and	HbA1c.	
	
	
Bibliography	
1.	Rubler	S	et	al.;	New	type	of	cardiomyopathy	associated	with	diabetic	glomerulosclerosis.	The	American	
journal	of	cardiology.	1972	Nov	08;30	(6):595-602.	PubMed	PMID:	4263660.	
2.	 Aneja	 A	 et	 al.;	 Diabetic	 cardiomyopathy:	 insights	 into	 pathogenesis,	 diagnostic	 challenges,	 and	
therapeutic	options.	The	American	journal	of	medicine.	2008	Sep;121(9):748-57.	PubMed	PMID:	18724960.	
3.	 Liu	 Q	 et	 al.;	 Diabetic	 cardiomyopathy	 and	 its	 mechanisms:	 role	 of	 oxidative	 stress	 and	 damage.		 J	
Diabetes	Investig.	2014	Nov;5(6):623-34	
4.	Poornima	IG	et	al.;	Diabetic	Cardiomyopathy.	The	search	for	a	unifying	hypothesis.	Circ	Res.	2006;98:596-
605.	
5.	Marwick	TH.	Diabetic	heart	disease.	Heart.	2006	Mar;92(3):296-300.	PubMed	PMID:	16159978.	Pubmed	
Central	PMCID:	1860832.	
6.	 Pappachan	 JM	 et	 al.;	 Diabetic	 cardiomyopathy:	 Pathophysiology,	 diagnostic	 evaluation	 and	
management.	World	J	Diabetes	2013	October	15;	4(5):	177-189].	
7.	Claus	Piet	et	al.;	Tissue	Tracking	Technology	for	Assessing	Cardiac	Mechanics.	Principles,	Normal	Values	
and	Clinical	Applications.	JACC	2015	December;	8	(12):1444-60.	
8.	Lorenzo-Almoros	et	al.;	Diagnostic	Approaches	for	Diaetic	cardiomyopathy.	Cardiovasc	Diabetol	2017;	16	
(28).	
9.	Mahrholdt	H	et	al.;	Assessment	of	myocardial	 viability	by	 cardiovascular	magnetic	 resonance	 imaging.	
European	heart	journal.	2002	Apr;23(8):602-19.	PubMed	PMID:	11969275.	
10.	 Schaefer	 S	 et	 al.;	 Gadolinium-DTPA-enhanced	 nuclear	 magnetic	 resonance	 imaging	 of	 reperfused	
myocardium:	 identification	 of	 the	myocardial	 bed	 at	 risk.	 Journal	 of	 the	 American	 College	 of	 Cardiology.	
1988	Oct;12(4):1064-72.	PubMed	PMID:	3417979.	
11.	Francone	M	et	al.;	Impact	of	primary	coronary	angioplasty	delay	on	myocardial	salvage,	infarct	size,	and	
microvascular	 damage	 in	 patients	 with	 ST-segment	 elevation	 myocardial	 infarction:	 insight	 from	
cardiovascular	 magnetic	 resonance.	 Journal	 of	 the	 American	 College	 of	 Cardiology.	 2009	 Dec	
01;54(23):2145-53.	PubMed	PMID:	19942086.	
12.	Giannetta	E	et	al.;	Chronic	Inhibition	of	cGMP	Phosphodiesterase	5°	Improves	Diabetic	Cardiomyopathy.	
Circulation	2012	May	15;125(19):2323-33.	
13.	Hamlin	S	et	al.;	Mapping	the	Future	of	Cardiac	MR	Imaging:	Case-based	Review	of	T1	and	T2	Mapping	
Technique.	RadioGraphics	2014;	34:1594–1611.	
14.	Sibley	CT	et	al.;	T1	Mapping	in	cardiomyopathy	at	cardiac	MR:	comparison	with	endomyocardial	biopsy.	
Radiology		2012	Dec;265(3):724-32.	
15.	 Iles	L	et	al.;	Evaluation	of	diffuse	myocardial	 fibrosis	 in	heart	 failure	with	cardiac	magnetic	 resonance	
contrast-enhanced	T1	mapping.	J	Am	Coll	Cardiol.	2008;52:1574	–1580.	
16.	Flett	AS	et	al.;	Equilibrium	contrast	cardiovascular	magnetic	resonance	for	the	measurement	of	diffuse	
myocardial	fibrosis:	preliminary	validation	in	humans.	Circulation.	2010;122:138	–144.	
17.	 Robbers	 LF,	 Baars	 EN,	 Brouwer	WP,	 Beek	 AM,	 Hofman	MB,	 Niessen	 HW,	 et	 al.;	 T1	 mapping	 shows	
increased	extracellular	matrix	size	in	the	myocardium	due	to	amyloid	depositions.	Circ	Cardiovasc	Imaging	
2012	May	1;5(3):423-6.		
18.	N.	Kawel,	M.	Nacif,	A.	Zavodni	et	al.,	T1	mapping	of	the	myocardium:	intra-individual	assessment	of	the	
effect	 of	 field	 strength,	 cardiac	 cycle	 and	 variation	 by	 myocardial	 region.	 	 Journal	 of	 Cardiovascular	
Magnetic	Resonance,	vol.	14,	p.	27,	2012.	
19.	 Wong	 et	 al.;Myocardial	 extracellular	 fraction	 quantified	 by	 cardiovascular	 magnetic	 resonance	 is	
increased	 in	 diabetes	 and	 associated	 with	 mortality	 and	 incident	 heart	 failure.	 European	 Heart	 Journal	
(2014)	35,	657-664.	
20.	 Abdel-Aty	 H	 et	 al.;	 Diagnostic	 performance	 of	 cardiovascular	 magnetic	 resonance	 in	 patients	 with	
suspected	acute	myocarditis:	comparison	of	different	approaches.	J	Am	Coll	Cardiol	2005;45:1815–22.	
21.	 Moon	 et	 al.;	 Myocardial	 T1	 mapping	 and	 extracellular	 volume	 quantification:	 a	 Society	 for	
Cardiovascular	Magnetic	Resonance	(SCMR)	and	CMR	Working	Group	of	the	European	Society	of	Cardiology	
consensus	statement	Journal	of	Cardiovascular	Magnetic	Resonance	2013,	15:92.	
22.	 Pennell	DJ,	 Sechtem	UP,	Higgins	CB,	 et	 al.:	 Clinical	 indications	 for	 cardiovascular	magnetic	 resonance	
(CMR):	Consensus	Panel	report.	EurHeart	J	2004,	25:1940–1965.	
23.	M.	Ugander,	AJ	et	al.;	Extracellular	volume	 imaging	by	magnetic	 resonance	 imaging	provides	 insights	
into	overt	and	sub-clinical	myocardial	pathology.	European	Heart	 Journal,	vol.	33,	no.	10,	pp.	1268–1278,	
2012.	
24.	Ng	AC	et	al.;	Association	between	diffuse	myocardial	 fibrosis	by	cardiac	magnetic	resonance	contrast-
enhanced	 T(1)	 mapping	 and	 subclinical	 myocardial	 dysfunction	 in	 diabetic	 patients:	 a	 pilot	 study,”	
Circulation	Cardiovascular	Imaging,	vol.	5,	no.	1,	pp.	51–59,	2012.	
25.	 Levelt	 E	 et	 al.;	 Relationship	 between	 left	 ventricular	 structural	 and	 metabolic	 remodeling	 in	 type	 2	
diabetes.	Diabetes,	vol.	65,	no.	1,	pp.	44–52,	2016.	
26.	 Khan	 JN	 et	 al.;	 Subclinical	 diastolic	 dysfunction	 in	 young	 adults	 with	 type	 2	 diabetes	 mellitus:	 a	
multiparametric	 contrast-enhanced	 cardiovascular	 magnetic	 resonance	 pilot	 study	 assessing	 potential	
mechanisms.	European	Heart	Journal.	Cardiovascular	Imaging	vol.	15,	no.	11,	pp.	1263–1269,	2014.	
27.	Zeng	M	et	al.;	The	Association	between	Diffuse	Myocardial	Fibrosis	on	Cardiac	Magnetic	Resonance	T1	
Mapping	and	Myocardial	Dysfunction	in	Diabetic	Rabbits.	Sci	Rep	2017	Mar	24;7:44937.	
28.	 Bugger	 H	 et	 al.;	Molecular	mechanisms	 of	 diabetic	 cardiomyopathy.	 Diabetologia,	 vol.	 57,	 no.	 4,	 pp.	
660–671,	2014.	
29.	Giacco	F	et	al.;	GLP-1	cleavage	product	reverses	persistent	ROS	generation	after	transient	hyperglycemia	
by	disrupting	an	ROS-generating	feedback	loop.	Diabetes,	vol.	64,	no.	9,	pp.	3273–3284,	2015.	
30.	 Huynh	 K	 et	 al.;	 Diabetic	 cardiomyopathy:	 mechanisms	 and	 new	 treatment	 strategies	 targeting	
antioxidant	signaling	pathways,”	Pharmacology	&	Therapeutics,	vol.	142,	no.	3,	pp.	375–415,	2014.	
31.	 Shang	 Y	 et	 al.;	 Assessment	 of	 Diabetic	 Cardiomyopathy	 by	 Cardiovascular	 Magnetic	 Resonance	 T1	
Mapping:	Correlation	with	Left-Ventricular	Diastolic	Dysfunction	and	Diabetic	Duration.	Journal	of	Diabetes	
Research	Volume	2017.	
32.	Lastra	G	et	al.;	Type	2	diabetes	mellitus	and	hypertension:	An	update.	Endocrinol	Metab	Clin	North	Am.	
2014	March	;	43(1):	103–122.	
33.	 Gazzaruso	 C	 et	 al.;	 Relationship	 Between	 Erectile	 Dysfunction	 and	 Silent	 Myocardial	 Ischemia	 in	
Apparently	Uncomplicated	Type	2	Diabetic	Patients.	Circulation	2004.	
34.	 Turkbey	 EB	 et	 al.;	Myocardial	 structure,	 function,	 and	 scar	 in	 patients	with	 type	 1	 diabetes	mellitus.	
Circulation.	2011;	124:1737–46.	
35.	Yoon	YE	et	al.;	Prognostic	significance	of	unrecognized	myocardial	infarction	detected	with	MR	imaging	
in	patients	with	impaired	fasting	glucose	compared	with	those	with	diabetes.	Radiology.	2012;	262:807–15.		
36.	Radunski	UK	et	al;	 “Identification	of	patients	with	myocarditis	by	 cardiovascular	magnetic	 resonance:	
T1-	 and	 T2-mapping	 are	 superior	 compared	 to	 conventional	 semi-quantitative	 techniques”	 Journal	 of	
Cardiovascular	Magnetic	Resonance	2014,	16(Suppl	1):P287.	
	
